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Abstract
Inhibition of blood coagulation via oral anticoagulant therapy is the mainstay for preventing a
cardioembolic stroke in patients with atrial fibrillation (AF). Factor Xa inhibitors (FXaIs),
rivaroxaban and apixaban, represent a new class of oral anticoagulants that are now widely
prescribed in AF patients as an alternative to traditional warfarin therapy. An important
advantage of these drugs is that routine monitoring of anticoagulation response is not
necessary. Nevertheless, because of their mechanism of action, FXaI antithrombotic effect can
be inferred based on the observed drug plasma concentration, with prolonged periods of
elevated FXaI systemic exposure associated with increased risk for major bleeding.

Currently, there is a paucity of data relating to observed interpatient variation in FXaI
plasma concentrations in the post-market clinical setting. Given that the patient population that
take FXaIs in the post-market setting may vary greatly with their co-morbidities and comedications from those within clinical trials, we hypothesized the systemic FXaI exposures
achieved in these individuals may vary greatly as well, and that this interpatient variation is
driven by patient-specific factors (physiology, disease-states, co-medications, genetics).

In the first study, we determined rivaroxaban and apixaban plasma concentrations in a
cohort of 243 AF patients during routine clinic visits, and found their measured FXaI
concentration tended to be more variable than those observed in clinical trials. Approximately
12% of patients receiving rivaroxaban and 13% of patients receiving apixaban exceeded the
predicted maximum FXaI plasma concentration observed in clinical trials.

In the second study, we characterized the observed variation in FXaI concentration
among our apixaban-treated AF cohort through regression analysis. Age and renal function
accounted for the majority of the explained variation, while female sex and amiodarone use
were also significant predictors of apixaban exposure. In addition, we demonstrated, for the
first time, that 4β-hydroxycholesterol plasma concentration, as a potential biomarker for
apixaban metabolism, was an independent predictor of interpatient variation in apixaban
concentration.
i

Equally important, we noted in our second study, that a large proportion of the
interpatient variation remained unaccounted for, and known common genetic variation in
metabolizing enzymes and efflux transporters did not significantly predict apixaban
concentration within our cohort. Therefore, we applied a custom targeted next-generation
exome sequencing approach (PGxSeq) to potentially identify rare or patient-specific single
nucleotide variation (SNV) in subjects with unexpectedly high drug concentration that result
in aberrant function or expression of apixaban metabolizing enzymes or transporters.
Following successful development and validation of PGxSeq, our exploratory analysis of
twelve apixaban-treated AF subjects that were sequenced, revealed rare and common SNV(s)
within the selected candidate genes.

Taken together, these studies provide insight into the factors that drive variation in
FXaI plasma concentration among AF patients in routine care, and serve as a framework for
future investigations regarding personalization of FXaI anticoagulant therapy.

Keywords:
Factor Xa inhibitor, apixaban, rivaroxaban, pharmacokinetics, interpatient variation, exome
sequencing, single nucleotide variants, pharmacogenetics
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1.1 Blood coagulation
Blood coagulation as part of a process known as hemostasis, is the body’s physiological response to blood vessel injury. Upon damage
to blood vessels, a chain of pro-inflammatory and wound-healing processes begin. This includes the formation of blood clots that are
rich in platelets, red blood cells, as well as fibrin protein, which prevents the loss of blood and allow recovery to commence. To date,
there are two prominent models that conceptualize coagulation; the “cascade” model was proposed first in the 1960s (1, 2), while the
“cell-based” model is more recent (3).

1.1.1

Cascade model

The cascade model depicts coagulation as a process that is directed and controlled by a series of interactions between protease zymogens,
enzymes, and cofactors known as coagulation factors that lead to the generation of thrombin and fibrin (Figure 1-1). Although this
model accurately depicts the interactions between individual coagulation factors, the concept that coagulation is segregated into two
distinct pathways, the intrinsic and extrinsic pathways, provides an inadequate explanation of hemostasis as it occurs in vivo. This
statement is supported by the observation that the factor VII protease/tissue factor complex of the extrinsic pathway is capable of
activating factor IX of the intrinsic pathway (4). Additionally, the downstream protease, thrombin has been shown to activate factor XI
of the intrinsic pathway (5). These findings were among the key steps that led to the understanding that the “intrinsic” and “extrinsic”

18

pathways are more interdependent than previously described.
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Figure 1-1. Cascade model of coagulation.
Abbreviations: TF , tissue factor

20
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1.1.2

Cell-based model

The cell-based model of blood coagulation is viewed as occurring in three successive non-exclusive phases: initiation, amplification,
and propagation (3)

22

Figure 1-2).
The initiation phase begins when tissue factor (TF, a membrane-bound protein)
from extravascular cells become exposed to blood constituents at the injury site.
Circulating factor VII is activated upon exposure to extravascular TF and then forms a
complex with TF (6), which subsequently activates factors X and IX. As circulating
platelets are exposed to the site of injury they adhere to collagen found in the extravascular
matrix and become partially activated. A consequence of platelet activation is the granular
secretion of partially activated factor V (7), which is a cofactor of the activated factor X
(FXa) protease. FXa can also further activate factor V (7). Activated factor V (FVa) can
combine with FXa on the cell surface of TF-expressing cells in the presence of calcium to
produce a small burst of thrombin protease at the injury site (8).
The thrombin generated during initiation amplifies the procoagulant state, by
activating platelets and coagulation factors, thereby setting the stage for the assembly of
procoagulant complexes on the surface of platelets to commence large-scale thrombin
generation. Thrombin is a potent activator of platelets via the protease-activated receptors
(PAR), where the enzyme cleaves a specific N-terminus peptide sequence from PARs to
unmask a tethered ligand that stimulates the receptor to induce downstream procoagulant
responses. The initial burst of thrombin also activates coagulation factors that are known
to be part of the “intrinsic” pathway, particularly factor XI (5, 8) and factor VIII (9). These
activated factors along with the aforementioned FVa are then recruited to the surface of
platelets, ready for the propagation phase.
During propagation, the initial burst of activated factor IX (FIXa) and factor X

1

(FXa) proteases combine with their respective co-factors on the surface of platelets to
assemble tenase (FIXa/FVIIIa) and prothrombinase (factor FXa/FVa) complexes. The
overall shift in procoagulant activity from TF-expressing cells towards platelets is
facilitated by an increased exposure of negatively charged phospholipids (e.g.,
phosphatidylserine) on the outer membrane leaflet of platelets that is secondary to their
activation (10). The presence of anionic phospholipids along with calcium is necessary for
the assembly and function of coagulation factors (11). Furthermore, given that each
activated protease is required for the subsequent activation of a downstream protease (e.g.,
FXIa activates FIX, FIXa is incorporated into a tenase (FIXa/FVIIIa) complex which
activates FX etc.) the close proximity of these enzymes on the platelet surface facilitates
the rapid burst of thrombin production required for a hemostatic fibrin clot.
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Figure 1-2. Cell-based model of coagulation.
In the cell-based model, coagulation occurs in three subsequent non-exclusive phases:
initiation, amplification, propagation. Trace amounts of thrombin are formed during the
initiation phase. In the amplification phase, the thrombin produced potentiates the
procoagulant state through cleavage activation of coagulation factors (FV, FVIII, FXI), and
PAR which is located on the surface of platelets. During the propagation phase, the
activated proteases and their co-factors form an assembly of coagulation complexes on the
surface of activated platelets, where their close proximity to one another facilitates the
large-scale thrombin generation required for a hemostatic clot. Abbreviations: PAR,
protease-activated receptors; TF, tissue factor; vWF, von Willebrand

4

1.2 Thrombosis
Maintaining normal blood fluidity requires a complex balancing of the procoagulant
(thrombus producing) and anticoagulant (thrombus inhibiting) processes. An imbalance of
these opposing processes gives rise to the potential for the formation of pathological
thrombi within the blood vessel. Thrombi can cause local obstruction of blood flow or
branch off and travel downstream to embolize elsewhere in the circulatory system in a
process known as thromboembolism. Thromboembolisms that obstruct blood flow to vital
organs such as the heart, brain, or lung can cause life-threatening complications. The
triggering events that lead to occlusive thrombus formation are consequence of one or more
of following: abnormal changes to the vascular wall, circulatory stasis, or a
hypercoagulable state (Figure 1-3). This combination of events was first elucidated by
Rudolf Virchow in the 1700’s and is known as Virchow’s “triad” (12).

5

Figure 1-3. Virchow’s triad.
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1.2.1

Venous thrombosis

The vascular environment plays an important role in the type of thrombus formed, as well
as in determining the associated clinical complications. Venous thrombosis most
commonly occurs within the deep veins of the leg where it is known as deep venous
thrombosis (DVT). It can be caused by stasis in venous circulation (e.g. prolonged bedrest),
as well as impaired local regulation of anticoagulant processes (e.g. protein C and S
deficiency). Clinical complications of DVT include edema and congestion in the vascular
beds distal to an obstruction; however, DVT is most problematic for its capacity to
originate pulmonary embolisms that cause death.

1.2.2

Arterial thrombosis

Typically, arterial thrombosis occurs following the rupture of an atherosclerotic plaque in
the presence of fast moving blood, with thrombus formation highly dependent on platelets.
A notable exception to this occurs in the case of atrial fibrillation (AF), since AF-related
thrombi are formed under low blood flow and are dependent upon the activation of the
coagulation cascade. The major complications of arterial thrombosis include the
obstruction of coronary and cerebral arteries causing cardiac ischemia (angina, myocardial
infarction) and ischemic stroke, respectively.

7

1.3 Thrombogenesis in the setting of atrial fibrillation
Atrial fibrillation is the most common pathological cardiac arrhythmia and is most
prevalent among the elderly (13). In 2010, the estimated number of men and women
affected by AF worldwide were 20.9 and 12.6 million, respectively (14). Cardiogenic
cerebral thromboembolisms resulting in ischemic stroke have long been strongly
associated with AF, dating back to the Framingham study in the early 1990s, which
reported a 5-fold greater incidence of stroke in those with AF as compared with diseasefree subjects (13).
Cardiogenic emboli in the setting of AF are also thought to be triggered by the
fulfillment of Virchow’s triad (15). During episodes of AF, the atrial myocardial tissue
experiences uncoordinated activation leading to ineffective contractions and reduced
cardiac flow, which promotes blood stasis, particularly in the left atrium and left atrial
appendage (LAA). The LAA, a long narrow inlet within the left atrium, is believed to be a
major source of cardiogenic emboli leading to ischemic stroke (16, 17). In addition to
stasis, structural changes in the form of atrial dilation and endocardial dysfunction are also
attributed to AF (16, 18-20). Finally, there is evidence of abnormal changes in blood
constituents that are indicative of a hypercoagulable state (15), thereby fulfilling Virchow’s
triad. For example, patients with AF exhibit elevated levels of the fibrin degradation
product, D-dimer (21, 22), and von-Willebrand factor (23, 24) compared to patients
without AF. Inflammatory cytokines (e.g. high-sensitivity C-reactive protein (25) and
interleukin 6 (26)) as well as growth factors (e.g. vascular endothelial growth factor (23,
27)) that stimulate TF production (28, 29), have been also found to be elevated in patients
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with AF, suggesting that inflammation as well as enhanced growth factors could also be
contributing to the hypercoaguable state in AF patients.

1.4 Stroke prevention in patients with atrial fibrillation
Oral anticoagulants (OACs) are the recommended preventative therapy for reducing stroke
risk in patients with AF (30-32). As a class, anticoagulants function by hindering fibrin
formation either through indirect or direct inhibition of coagulation factor(s). Compared to
antiplatelets, which inhibit platelet activation or aggregation, OACs are more effective at
reducing stroke and mortality incidence in AF patients (33, 34). The effectiveness of OACs
over antiplatelets can be attributed to the fibrin-rich, low-platelet nature of AF-related
thrombi (35).

1.4.1

Therapeutic interventions

The recommendation for use of OACs in the setting of AF is based on a patient’s assessed
stroke risk (31), which is increased by the presence of additional clinical factors such as
advanced age, hypertension, and diabetes mellitus (36). Therefore, prediction formulas
such as CHADS2 (36) and CHA2DS2-VASc (37) (defined in Table 1-1 and Table 1-2)
have been developed to stratify patients with AF in order to identify those that might benefit
from receiving anticoagulant therapy. For example, according to the 2016 Canadian
Cardiovascular Society guidelines for management of AF patients, OAC therapy is
recommended for AF patients that are ≥ 65 years of age or for younger patients with
CHADS2 score ≥ 1(38).
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Table 1-1. CHADS2 stroke risk stratification schema for patients with atrial
fibrillation
Points†

CHADS2
C

Congestive heart failure

1

H

Hypertension

1

A

Age ≥75

1

D

Diabetes mellitus

1

S

Prior stroke or transient ischemic attack

2

† Based on the number of risk factors an individual possesses these points are summed to
calculate their CHADS2 score value.

Table 1-2. CHA2DS2-VASc stroke risk stratification schema for patients with atrial
fibrillation.
Points†

CHA2DS2VASc
C

Congestive heart failure (Left ventricular ejection fraction ≤40%)

1

H

Hypertension

1

A

Age ≥75 years

2

D

Diabetes mellitus

1

S

Prior stroke/transient ischemic attack/thromboembolism

2

V

Vascular disease

1

A

Age 64-74 years

1

S

Female sex

1

†Based on the number of risk factors an individual possesses these points are summed to
calculate their CHA2DS2VASc score value.
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1.4.2

Warfarin

Warfarin was the first OAC widely used as a prophylactic for stroke prevention in patients
with AF. Its use is associated with a 64% reduction in stroke incidence compared to placebo
(39). Warfarin indirectly depletes the biologically active supply of key vitamin Kdependent clotting factors (II, VII, IX, X, protein C and S) through its action as a Vitamin
K epoxide reductase antagonist. While warfarin is highly effective at reducing stroke risk,
major bleeding remains a significant safety concern with its long-term use.

1.4.3
1.4.3.1

Direct-acting oral anticoagulants
Phase III clinical trial data

The advent of the next generation of OACs was enabled by the discovery of the crystal
structures of the key coagulation factors thrombin (40) and factor Xa (41). Small molecule
inhibitors called direct-acting oral anticoagulants (DOACs) were developed to directly
target these rate limiting enzymes. Four pivotal randomized control trials (RCT) that
compared the efficacy and safety outcomes of each of these drugs to warfarin were
published between 2009 and 2013 (42-45). Dabigatran, the first thrombin inhibitor to be
approved, was found to be equally efficacious as warfarin for prevention of stroke and
systemic embolism (SSE) in AF patients and had comparable adverse bleeding rates. This
was followed by the approval of the factor Xa inhibitors rivaroxaban, apixaban, and
edoxaban. Compared to warfarin, apixaban was superior in reducing SSE events and had
lower rates of bleeding, while rivaroxaban and edoxaban had comparable rates of SSE. The
rates of bleeding were lower for edoxaban when compared to warfarin, however were
comparable between rivaroxaban and warfarin. Further meta-analysis of pooled data from
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all four trials found that the greatest benefit of the DOACs class was a substantially reduced
rate of intracranial hemorrhage, which is a potentially fatal complication of OAC treatment,
while the greatest detriment was a higher rate of gastrointestinal bleeding (46). Thus
overall, RCT data concluded that DOACs offer a favourable balance of safety and efficacy
compared to warfarin.

1.4.3.2

Dosing and administration

The initial dose selection is straightforward for DOACs. Patients are given either the
standard dose or a reduced dose based upon meeting specific clinical criteria such as renal
impairment, low body weight, and interacting medications. The recommended dose of
dabigatran is 150 mg twice daily or 110 mg twice daily if patients are aged ≥ 80 years (47).
Rivaroxaban is to be taken with food at a standard dose of 20 mg once daily, unless patients
have moderate renal impairment with an estimated creatinine clearance ranging between
30 and 49 mL/min (48). The recommended dosage for apixaban is 5 mg twice daily, or 2.5mg twice daily for patients fulfilling two of the three following clinical criteria: age ≥ 80
years, serum creatinine value ≥ 133 mmol/L, and weight ≥ 60 kg (49). Edoxaban has a
recommended dose of 60 mg once daily or 30 mg once daily in patients with one or more
of the following clinical criteria: moderate renal impairment as defined above, body weight
≤ 60 kg, or a taking an interacting medication such as a P-glycoprotein inhibitor (50).
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1.5 Clinical and genetic determinants of optimal oral
anticoagulant therapy
Given the mechanisms by which OACs elicit their effects, differences in drug response are
a concern for adverse reactions. The efficacy of OACs in reducing stroke or systemic
embolic events is counter-weighed by the risk of major bleeding events, including bleeds
that result in death by exsanguination, symptomatic bleeding into critical sites or organs
(e.g. intracranial or gastrointestinal), a hemoglobin drop ≥2 g/dL, or the necessity of a blood
transfusion. Therefore, achieving balanced anticoagulation is critical for maximizing the
safety and efficacy of OACs.

1.5.1

Warfarin

The earliest attempts at long-term warfarin use were complicated by unacceptably high
bleeding rates (51, 52). Subsequently, it was found that lower intensity anticoagulation
regimens monitored carefully by hemostatic testing using the prothrombin time (PT) test
could be as effective (Figure 1-4), but safer than high-intensity regimens (53, 54),
improving the safety of warfarin use in patients. PT test measures the clotting tendency of
blood determined as the time required for a blood sample to clot, specifically evaluating
the extrinsic pathway of coagulation (factors I, II, V, VII, X), where warfarin treated
samples would have longer PT times, then untreated samples. In the 1980s, prothrombin
international normalized ratio (INR) was introduced by the World Health Organization
(WHO), which globally standardized the PT test for assessing anticoagulation. Today,
warfarin dosing is based on achieving a target INR value of between 2.0 and 3.0 for AF
patients (54). However, in order to achieve this therapeutic range in patients, prescribers
13

must accommodate an up to 20-fold variation in warfarin dose that exists between
individuals. Aside from demographic (age, sex, weight) and clinical variables (renal or
hepatic disease, dietary, interacting medication), there is a significant contribution from
genetic variation within the proteins involved in warfarin’s metabolic and/or drug response
pathway that complicate achieving a therapeutic warfarin dose.

Figure 1-4. International normalized ratio and prothrombin time
International normalized ratio (INR) is expressed as the relationship between the
prothrombin time of a warfarin-treated blood sample over the prothrombin of an untreated
sample. INR values between 2.0 and 3.0 provide greatest therapeutic benefit. INR values
less than 2 and greater than 4 are associated with increased risk of stroke and hemorrhage,
respectively.
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1.5.1.1

Mechanistic determinants of warfarin dose response

Warfarin is administered as a racemic mixture of two active enantiomers (R- and Sisomers) that are rapidly absorbed from the gastrointestinal tract at high oral bioavailability
(product monograph). After absorption, the drug accumulates in the liver and functions as
an inhibitor of the Vitamin K epoxide reductase enzyme (VKORC1) with the S isomer as
the stronger antagonist (55, 56). Warfarin is almost entirely excreted through the urine in
the metabolite form (57). The two enantiomers undergo metabolism by different
cytochrome P450 (CYP) enzymes (58), with the inhibition of S-warfarin metabolism being
of greater clinical relevance.
The more potent enantiomer, S-warfarin, is metabolized by CYP2C9 into its
inactive form S-7-hydroxywarfarin (58). However, the CYP2C9 gene has several genetic
variations, of which the CYP2C9*2 and CYP2C9*3 polymorphisms show decreased
enzymatic hydroxylation of S-warfarin in vitro (59, 60). The allele frequencies for
CYP2C9*2 (c.430 C>T) and CYP2C9*3 (c.1075 A>C) are approximately 12.5% and 8.5%
in Caucasian populations (61), although these numbers vary based on ancestry. Genotyping
for these alleles have demonstrated that variant carriers have reduced S-warfarin clearance
(57), reduced warfarin dose requirements (62, 63), and increased risk of over
anticoagulation. In a meta-analysis of nine studies including 2275 patients, variant carriers
of CYP2C9*2 and CYP2C9*3 had an average dose reduction of 17% and 37%,
respectively, compared to CYP2C9*1 (wildtype) (64).
Warfarin elicits its anticoagulant effect on the enzyme VKORC1, which is involved
in the cyclic interconversion of Vitamin K (Figure 1-5) as part of the physiological
recycling of Vitamin K1 dihydroquinone (65). Vitamin K1 dihydroquinone (VKH2) is an
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essential cofactor in the post-translation carboxylation of N-terminal glutamate residues on
Vitamin-K dependent coagulation proteins (65). These proteins, which include coagulation
factors II, VII, IX, and X as well as anticoagulant factors protein C and protein S, require
carboxylation to render them biologically active (65). Gamma-glutamyl carboxylase is
responsible for carrying out this reaction using VKH2, CO2, and O2. VKH2 is converted to
Vitamin K epoxide as a product of the reaction. VKORC1 is then responsible for the
chemical reduction of vitamin K epoxide to vitamin K1, an intermediate that is further
reduced to vitamin K1 dihydroquinone (65). Therefore, by inhibiting VKORC1, warfarin
impedes the vitamin K cycle and depletes the biologically active supply of vitamin K
dependent coagulation factors.
Identification of the VKORC1 gene (66) led to investigations of the effect of VKORC1
genetic variation on warfarin dosing. Several studies identified a single nucleotide
polymorphism (c.-1639 G>A, *2) located within the promoter region of the gene that was
associated with dose response to warfarin as measured by INR (67-70). Carriers of this
polymorphism were more sensitive to warfarin and required a lower dosage to achieve the
target INR (67-70), independent of the CYP2C9 genetic variation. The molecular
mechanism behind this warfarin sensitivity is believed to be at the transcriptional level, as
demonstrated in vitro with the -1639A allele having reduced VKORC1 promoter activity
(68, 69).
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Figure 1-5. Vitamin K cycle, and the involvement of warfarin, Vitamin K epoxide
reductase, CYP2C9, and CYP4F2.
Warfarin effectively lowers the supply of biologically active coagulation factors by
inhibiting the conversion of Vitamin K epoxide (oxidized form) to Vitmain K
dihydroquinone (reduced form). Vitamin K dihydroquinone is a cofactor required for the
post-translation carboxylation of amino-terminus residues on key coagulation factors (II,
VII, IX, X); a process that is essential for rendering these proteins biologically active.
Vitamin K epoxide (oxidized form) is product of this carboxylation reaction, and Vitamin
K epoxide reductase is responsible for converting the oxidized product back into Vitamin
K dihydroquinone. CYP4F2 is a vitamin K1 oxidase, and is believed to be involvement in
the removal of Vitamin K1 quinone from the Vitamin K cycle. Abbreviations: CYP,
cytochrome P450 enzyme.

17

Studies using multiple regression analysis to examine the combined effect of
CYP2C9 and VKORC1 polymorphisms, as well as clinical variables (age, sex, body surface
area, interacting medications), found that the proportion of inter-individual variability in
warfarin dosage accounted for by genetic factors was greater than that explained by clinical
variables (36, 71). In a study designed to develop a warfarin-dosing algorithm, authors
were able to explain 53-54% of the variability in warfarin doses using genetic factors along
with clinical variables (age, body surface area, interacting medications, and indication for
warfarin use), while clinical variables alone explained only 17-22% of dose variability
(72). This observation was replicated in a later study where CYP2C9*2 and *3
polymorphisms explained a combined 12% of the variation in warfarin dose, while the
VKORC1*2 polymorphism explained 30%, and an additional 15% was explained by
clinical variables (71).
Unbiased detection of statistical associations between specific regions in the
genome and a clinical outcome of interest can be accomplished using genome-wide
association (GWA) studies. In two GWA studies that screened up to 550,000 SNPs
spanning the whole genome in sample sizes of 300 and 1000 Caucasians, it was found that
the statistical signals emanated from the VKORC1 gene, followed by CYP2C9 gene (73,
74).
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1.5.1.2

Randomized control trial evidence for genomic-guided warfarin
therapy

The large amount of evidence on the impact of genetic factors on warfarin dosing has given
rise to a number of pharmacogenomic-guided dosing algorithms that incorporate CYP2C9
and VKORC1 genotypes along with clinical variables for predicting warfarin initiation and
maintenance doses (72, 75, 76). However, determining the net clinical benefit of the
implementation of such algorithms into clinical practice has been challenging with RCT
bearing positive and neutral results for genomics-guided dosing.
The Clarification of Optimal Anticoagulation through Genetics (COAG) trial and
two European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trials were
published in 2013. These trials measured the benefit of genetic-guided warfarin dosing in
patients with AF or venous thromboembolism using time in therapeutic range (TTR) as the
primary outcome (77-79). TTR is a useful proxy measure for clinical risk of bleeding (overanticoagulation) or thrombosis (under-anticoagulation) as these studies were not
sufficiently powered to detect differences in these outcomes directly. Two of the trials
compared genomics-guided dosing with a clinical variables algorithm and found no
statistical difference in the percentage TTR at the end of their respective follow up periods
of four or twelve weeks (77, 78). The third trial compared a genomics-guided algorithm to
standard dosing (no algorithm), which is more representative of usual care, and found
significant benefits to using the genomics-guided algorithm (79). The authors reported a
greater TTR, fewer incidences of elevated INR, and shorter times to therapeutic range when
using their pharmacogenetic algorithm (79).
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In 2017, the Genetic Informatics Trial (GIFT) compared genotype-guided dosing
versus a clinical algorithm in initiating warfarin therapy for prevention of venous
thromboembolisms (VTE) in older subjects (≥65 years) following knee or hip surgery (80).
The primary outcome was a composite of INR ≥4, major bleeding, VTE, or death.
Genomics-guided dosing resulted in a statistically significant reduction of the composite
primary outcome. Notably, the authors of this study included an additional variant,
CYP4F2*2, in their genotyping testing.
The conflicting results from these RCTs have instigated criticism regarding the
design and execution of these studies as well as debate surrounding the value of genomicsguided warfarin dosing (81). For instance, the 2013 EU-PACT trial had positive findings
using standard dosing (with dose tailored only to age) as their control arm rather than a
clinical algorithm, essentially testing a hypothesis that differs from the other trials. In
addition, it is well known that there are ethnic differences in the prevalence of CYP2C9
and VKORC1 variant genotypes (82, 83), underscoring the importance of tailoring the
variants included within a pharmacogenomics-guided dosing algorithm to account for
prevalence of those alleles within the tested ethnic population. In the negative COAG trial,
nearly 30% of participants were of African descent, yet the variants tested did not include
VKORC1 and CYP2C9 variants that are more prevalent and predictive of warfarin dosing
among African populations. Some authors believe this may have negatively impacted the
genomic-guided arm by overdosing some African patients (81). Lastly, both the positive
EU-PACT trial and the GIFT trial performed preemptive genotyping, where the variant
status was known prior to initiating warfarin. Conversely, in the COAG trial only 45% of
patients within the genomics-guided group had their variant status available for
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incorporating into the dosing algorithm prior to receiving their first dose. Some authors
argue that the greatest benefit for genomics-guided dosing is achieved during the initiation
phase of warfarin dosing (81). Overall, it appears that the greatest clinical benefit is
achieved when using genomic-guided algorithms for the initial warfarin dose selection in
patients preemptively genotyped for variants tailored to their ancestry (84).

1.5.2

Next generation of oral anticoagulants

Not surprisingly, given the issues surrounding warfarin, direct-acting oral anticoagulants
(DOAC) were developed and are now approved as an alternative therapy for stroke
prevention in patients with AF, as well as prevention of venous thromboembolisms. Since
their approval, the use of these drug in AF patients has rapidly increased (85, 86), owing
to their ease of prescribing and management. While warfarin prescribing was complicated
by routine INR testing and a high interpatient variability in the therapeutic dosage, DOACs
offer fixed dosing (up to 2-fold) without the need for routine monitoring. Although DOACs
appear to be safer than warfarin, major bleeding is still a complication associated with
DOAC use. Furthermore, the patient population that take DOACs in the post-market setting
may vary greatly with their co-morbidities and extensive co-medications from the often
idealistic settings that exists within clinical trials. As prescribing trends in clinical practice
continue to favour the use of DOACs, the number of bleeding events associated with them
is likely to increase as well. Identifying factors that increase the DOAC-associated bleeding
risk in patients before prescribing these drugs can help to mitigate adverse drug events.
Factors that increase DOAC bleeding risk can be categorized into the following: advanced
age (≥75 years), co-medication with pharmacodynamic interactions, medical conditions or
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procedures with pre-existing bleeding risks, as well as factors that increase DOAC plasma
concentrations.
Although there are a number of DOACs currently available on the market,
the remainder of this thesis will be focused on the factor Xa inhibitors, rivaroxaban
and apixaban, as the patient population we investigated were primarily prescribed
these DOACs.

1.5.3
1.5.3.1

Factor Xa Inhibitors
Significance of factor Xa inhibitor drug exposure

The factor Xa inhibitors (FXaIs), rivaroxaban and apixaban, have a pharmacological effect
that is closely correlated to their blood concentration (87-90). Taken orally, FXaIs are
absorbed at the level of the intestine, then enter the systemic blood circulation (at 50-100%
bioavailability see Table 1-3) where they act on their circulating target, which is the
activated coagulation protein factor Xa (FXa). Through reversibly binding to the active site
of FXa with high affinity, these drugs effectively inhibit the catalytic activity of both free
and prothrombinase-bound FXa (91, 92). From a pharmacological standpoint, this ability
of rivaroxaban and apixaban to directly inhibit factor Xa, allows them to have a rapid onset
and offset of action that is measured in hours (87, 89), unlike warfarin, which takes days
to produce therapeutic efficacy (57). Inhibition of factor Xa reduces thrombin generation
and consequently hinders clot formation given thrombin’s effects on fibrin formation and
platelet activation. In vitro studies investigating factor Xa activity at varying concentrations
of FXaI in human blood plasma have shown a positive relationship between increasing
rivaroxaban and apixaban concentration and factor Xa inhibition (89, 93). Animal models
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used to study FXaI antithrombotic efficacy have shown that a reduction in thrombus
formation correlates with increased FXaI dose (92, 93). Hemostatic testing of FXaI-treated
patient plasma samples to measure the sample’s ability to clot under standard conditions
also show a concentration-dependent relationship, with longer clotting times as drug
concentrations increase in plasma (89, 93).
The potential relationship between the circulating concentration of FXaI and harm
such as major bleeding in contrast to its efficacy in stroke prevention in AF or VTE in total
knee/hip replacement was noted in the Food and Drug Administration (FDA)’s clinical
pharmacology and biopharmaceutics reviews documents, which reported that elevated
rivaroxaban and apixaban exposure were associated with increased risk of bleeding (94,
95). Similarly, the more recently approved FXaI, edoxaban, was also found to have this
positive relationship between bleeding events and plasma concentration (96).
Consequently, patient factors that increase FXaI plasma concentration is among the listed
factors to influence risk of hemorrhage (48, 49).
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Table 1-3. Summary of the pharmacokinetic parameters for rivaroxaban and
apixaban in healthy subjects.
Parameter

Rivaroxaban

Apixaban

Factor Xa inhibitor

Factor Xa inhibitor

>80* (97)

50 (98)

Tmax, hours

2-4 (48)

1.5-3.3 (88)

T1/2, hours

11-13 (48)

12 (49)

Protein binding, %

92-95 (48)

87-93 (99)

10 (48)

3.3 (49)

30-40 (48)

27 (98)

50 (48)

21(98)

Increase AUC by 39%

None (88)

Mechanism of action
Bioavailability, %

Total Clearance, L/h †
Renal clearance, % (of total
clearance) †
Vss , L
Food effect

(97)
Renal excretion, % ‡

36 (100)

22 (101, 102)

Fecal excretion, % ‡

7 (100)

34 (101, 102)

CYP3A4/5, CYP2J2

CYP3A4/5 (104)

CYP-mediated metabolism

(103)
Drug transporters

P-gp, BCRP (105)

P-gp, BCRP (106)

Abbreviation: AUC, area-under-the-curve; BCRP, breast cancer resistance protein; Cmax, maximum
concentration; FXa Ki, inhibition constant of Factor Xa enzyme; T1/2 , terminal elimination half-life; Tmax,
time at maximum concentration; P-gp, P-glycoprotein; Vss , volume of distribution at steady-state. (†) After
intravenous administration; (‡) Percent recovery of unchanged radio-labelled drug; (*) Bioavailability is
80-100% when taken with food, or 66% without food.
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1.5.3.2

Determinants of FXaI exposure

Phase I pharmacokinetic studies have explored the impact of renal function, advanced age,
and extremes of weight on rivaroxaban and apixaban exposure, often measured as the area
underneath the plasma concentration time profile or area-underneath-the-curve (AUC).
Kidney function is a strong determinant of FXaI drug exposure as both drugs undergo
urinary excretion as part of their elimination process. Individuals with impaired renal
function exhibit reduced total clearance and increased drug exposure, such that subjects
with mild, moderate, and severe renal impairment were associated with ~16%, ~29%, and
~44% higher AUC values for apixaban and ~44%, ~52%, and ~64% for rivaroxaban,
respectively (107, 108). Advanced age has been shown to influence FXaI total clearance
resulting in modest increases in drug exposure in subjects ≥65 years for apixaban (32%
higher AUC compared to those aged 18-40 years) (109) and subjects >75 years for
rivaroxaban (41% higher AUC compared to those aged 18-45 years) (110). However,
differences in renal function between these age groups is likely to contribute to these
effects. Body weight greater than or equal to 120 kg has been shown to lower the apixaban
AUC by 23%, while body weights less than or equal to 50 kg have a 20% increase in
apixaban AUC (111). In comparison, extremes of weight appear to have minimal effect on
rivaroxaban exposure (112).
Modulation of the metabolizing enzymes or transporters that are responsible for
apixaban and rivaroxaban disposition can alter the drug concentrations achieved in the
blood. FXaI drug metabolism is mediated primarily through the oxidative cytochrome
P450 enzymes CYP3A4/5 and CYP2J2, although the latter applies only to rivaroxaban
(103, 104). In vitro studies suggest rivaroxaban and apixaban are substrates to the efflux
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transporters, P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP,
ABCG2), which are expressed highly in the intestine where these transporters influence
FXaI absorption and in the kidneys where they influence renal excretion (105, 106).
Concomitant medications that interact with these proteins or functional genetic variants
that exist within their respective genes might be associated with increased systemic FXaI
exposure and contribute to inter-individual variation in drug concentration. In particular,
concomitant use of potent inhibitors and inducers of CYP3A4 such as ketoconazole and
rifampin, respectively, have been shown to alter apixaban and rivaroxaban exposure by up
to 50% change in the AUC by increasing and decreasing FXaI concentrations, respectively
(48, 98, 113, 114). Recent work from Ueshima et al. in a Japanese AF population
demonstrated that the ABCG2 421A/A genotype was associated with higher apixaban
plasma concentrations at trough and reduced clearance, whilst the CYP3A5*1/*1 genotype
was associated with lower concentrations at trough and higher clearance (115, 116). Refer
to Figure 1.5 for the proposed disposition of apixaban and rivaroxaban, as well as Table
1-3 for a summary of their pharmacokinetic parameters.
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Figure 1-6. Proposed disposition of rivaroxaban and apixaban.
Data represents percent of orally administered radio-labelled dose that is excreted in urine versus feces, taken from mass-balance
studies carried in healthy human subjects (100, 101). Abbreviations: BCRP, breast cancer resistance protein; CYP, cytochrome P450
enzyme; GI, gastrointestinal tract; P-gp, P-glycoprotein
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1.6

Human genetic variation and pharmacogenetics

Sequencing the human genome (117-119) accelerated investigations of the influence of
genetic variation on human health and disease. Within the roughly 3.1 billion base pairs of
the average human genome, over 12 million common sequence variations (excluding
structural variants) (120) have been identified across world populations. These variations
can be classified according to their prevalence within a specific population as well as by
their nucleotide composition. The latter can be further categorized into structural or single
nucleotide variants (
Figure 1-7).

1.6.1

Single nucleotide variants

Single nucleotide variants (SNVs) are sequence variations that occur throughout the
genome, in which a single deoxyribonucleic acid (DNA) base pair is substituted for
another. They are the most abundant form of genetic variation and based on the frequency
of the minor allele in a human population, are referred to as either common or rare SNVs.
Common SNVs, also called single nucleotide polymorphisms (SNPs), have a minor allele
frequency (MAF) of at least 1%, with most having a frequency greater than 5%. The vast
majority of SNVs that are present in an individual are common (121). Rare or novel de
novo SNVs have a MAF less than 1%, and are sometimes referred to as a mutation,
especially when they have a confirmed deleterious effect.
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Figure 1-7. Types of genetic variation.
Genetic variation can be classified based on the number of nucleotides that are implicated,
which can range from as small as a single nucleotide variant all the way up to a complete
loss or gain of a chromosome (aneuploidy).
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Aside from allele frequency, SNVs can differ in their location with respect to a
gene, and their translated effect at the protein level (Figure 1-8). Within the coding region,
areas of the genome that undergo transcription and translation, nucleotide substitutions
have the potential to alter the amino acid sequence of a polypeptide. A synonymous SNV
is defined as a nucleotide substitution that creates a codon that codes for the same amino
acid. Nonsynonymous SNVs occur when a nucleotide substitution creates a codon that
either codes for a different amino acid or a premature stop codon. These variants have
potential implications on the structure and/or function of a protein. In addition, SNVs can
reside within noncoding regions. SNVs that occur within intron-exon boundaries can
interrupt the splicing pattern required to form the appropriate messenger ribonucleic acid
(mRNA) transcript required for a functional protein. Furthermore, SNVs can occur within
regulatory elements (which include promoters, enhancers, repressors) and potentially alter
the expression of a gene.

Figure 1-8. Type of single nucleotide variation.
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1.6.2

Evolution of pharmacogenetics

In pharmacology, an individual’s response to a drug can be considered a phenotype,
whether the individual is experiencing toxicity or the desired pharmacological effect.
Pharmacogenetics is the study of the influence of genetic variation on drug response,
typically by way of altering pharmacokinetics (absorption, distribution, metabolism, or
elimination) or pharmacodynamics (target of a drug, or drug sensitivity). Prior to recent
advancements, the discoveries that shaped the field of pharmacogenetics came from
studying families for patterns of inheritance for specific drug responses, eventually leading
to molecular studies that revealed the genetic determinant for that response phenotype
(122). Pharmacogenetic research was greatly advanced by the elucidation of the human
genome sequence and identification of the common genetic variations within the human
population, together with developments in sequencing and genotyping technologies. While
previous strategies relied on the candidate-gene approach (pre-selection of genes based on
a priori knowledge), SNP genotyping arrays have enabled unbiased genome-wide analyses
associating SNPs to drug phenotypes through GWA studies. There have been a number of
important genotype-phenotype associations identified in pharmacogenetics using GWA
studies (123-126). A prominent example of this is the association of common SNVs within
the genes, CYP2C9 and VKORC1, with variability in warfarin drug response (73, 74). To
date, these arrays have been used to identify several common polymorphisms as genetic
factors that influence variability in drug response. Unfortunately, the commonly used
genotyping platforms limit the identification of rare or novel SNVs, thus the investigation
of rare variations requires more comprehensive sequencing technologies.
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1.7 DNA sequencing technologies
DNA sequencing technologies have improved greatly over the past twenty years, reducing
the cost and time requirements of large scale sequencing projects. Interestingly, the initial
sequencing of the human genome (117) was carried out using a method developed in 1977
(127) by Sanger and his colleagues now known as “Sanger” sequencing. This method was
part of a first generation of sequencing technologies, has now been succeeded by a second
generation of sequencing technologies. These next generation sequencing (NGS) platforms
that drastically improved sequencing cost and time through massive parallelization of
sequencing reactions achieved by miniaturizing sequencing reactions and improving
detection systems.

1.7.1

Sanger sequencing

In this approach, a single stranded DNA template is replicated several times over using
DNA polymerase, an oligonucleotide primer, deoxyribonucleotide-triphosphates (dNTPs),
and fluorescently labelled dideoxyribonucleotide-triphosphates (ddNTPs). During DNA
synthesis, the incorporation of ddNTPs terminates the elongation of the complementary
strand as ddNTPs lack the required 3ʹOH for elongation. The presence of both ddNTP and
dNTP enables the synthesis of complementary DNA strands of varying lengths with one
of four fluorescently labelled ddNTPs (ddATP, ddTTP, ddGTP, ddCTP) on their 3ʹ ends.
After several rounds of template DNA extension, the resulting reaction product is injected
onto a capillary and separated according to size with the smallest fragments undergoing
excitation and detection of fluorescence signal first. This produces four electropherograms
that are superimposed to produce the final sequence. The major drawbacks of this method
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are the price per base and its inefficiency for large scale sequencing projects. Sanger
sequencing of the human genome in the Human Genome Project was a 13-year, $2.7 billion
effort.

1.7.2

Illumina sequencing

Today, the Illumina sequencer is one of the most commonly used next generation
sequencing (NGS) platforms. The methodology involves bridge amplification to produce
clusters of clonally enriched template DNA that are then sequenced in a sequencing-bysynthesis manner.

1.7.2.1

Cluster generation

First, template DNA is fragmented and two different sets of adapters are attached to the
termini of each fragment. The adapters serve as an annealing site for sequencing primers,
as well as a method of attachment to the flow cell (sequencing apparatus). Next, fragments
are denatured to form single stranded template DNA that is injected into the flow cell. The
flow cell is a glass surface densely coated with different oligonucleotides that are
complementary in sequence to the adapters at each end of the template DNA, so that upon
injection, the fragments become attached to the surface of the flow cell. Then, a polymerase
creates a complement of the hybridized fragment and the original template DNA is washed
away. The remaining fragments are then amplified through bridge amplification,
transforming single fragments into clonal clusters.
Bridge amplification begins with an annealing step, where the free adapter end tips
over and hybridizes to a complementary oligonucleotide on the flow cell forming a bridge.
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Next, polymerase chain reaction (PCR) reagents are added to synthesize the
complementary strand. Then, the two strands are denatured, which disassociates the bridge.
This process of bridge amplification is cycled repeatedly until each cluster contains
approximately 1000 clonally amplified fragments, at which point they are ready for
sequencing.

1.7.2.2

Sequencing-by-synthesis

The first cycle of sequencing begins with the introduction of DNA polymerase, a primer,
and four fluorescently-labelled nucleotides into the flow cell. After primer annealing, a
single complementary dNTP is incorporated, and the excess dNTPs are washed away. The
fluorescent label also serves to terminate further extension of the sequence, so that only
one nucleotide is added at a time. The fluorescent dyes are then excited and an image is
taken, capturing an emitted signal for each cluster in the flow cell. The chemical groups
containing the fluorescent dye are enzymatically removed recovering the 3ʹOH group, to
allow for the next cycle of dNTPs to be added and imaged. These series of images are then
assembled and analyzed by computer software to put together the sequence for the tens of
millions of clusters.

1.7.3

Targeted exome sequencing

Although NGS enables the unbiased detection of common, rare, or novel variations, whole
genome sequencing is still a costly endeavour. This cost encompasses the price for
sequencing as well as data storage and processing. Exome sequencing is a more focused
method of sequencing that is limited to the protein coding regions, which comprise
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approximately 1% of the human genome (128). These “targeted” exome capture strategies
enable deep sequencing of a relatively small number of selected genes of interest
(cumulatively less than 1,000,000 bp), decreasing error rates and uncertainly in genotype
calling that are frequently associated with short-read NGS data (129). Fundamentally,
targeted exome NGS (Figure 1-9) requires the capture and enrichment of genomic regions
of interest before sequencing. The target-enrichment strategies that can be used include
PCR-based, molecular inversion probe (MIP)-based, or hybrid oligonucleotide capturebased approaches, all of which can vary in their performance relative to one another (130).
The possibility of using NGS to sequence genes pertinent to drug disposition and drug
response is of particular relevance in the fields of pharmacogenetic research and clinical
genotyping to implement personalized genotype-based therapies
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Figure 1-9. Targeted next generation sequencing workflow.
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1.8 Summary
Factor Xa inhibitors (FXaIs), rivaroxaban and apixaban, represent a new class of oral
anticoagulants that are a safe and efficacious alternative to warfarin therapy for stroke
prevention in patients with AF. Given their mechanism of action, FXaI pharmacological
effect can be inferred based on the observed plasma drug concentration. Consequently,
prolonged periods of elevated FXaI concentration are associated with increased risk for
major bleeding. Currently, there is a paucity of data relating to observed interpatient
variation in FXaI plasma concentrations in the post-market clinical setting. The patient
population that take FXaIs in the post-market setting may vary greatly with their comorbidities and extensive co-medications from those within clinical trials. Therefore, the
systemic FXaI exposures achieved in these individuals may vary greater than those
observed in clinical trials, and this interpatient variation is likely driven by patient-specific
factors that comprise an individual’s physiology, disease-state, environment (e.g. comedications, food), as well as genetics. Renal impairment, age, sex, extremes in weight, as
well as common single nucleotide variants (SNVs) in metabolizing enzymes and
transporters that are responsible for apixaban and rivaroxaban disposition have been
indicated to alter the elimination of FXaIs from the body, and are predictive of systemic
apixaban exposure. Similarly, endogenous biomarkers of FXaI metabolism may serve as
an additional predictor of drug exposure. While previous research surrounding the
influence of genetics on drug exposure has been focused on evaluating common functional
variation, more recent evidence suggest rare SNVs in drug processing genes may also
significantly contribute to interpatient differences in drug disposition beyond established
common genetic predictors (131-133). Thus it is intriguing to speculate that AF patients
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who demonstrate unexpectedly high or low FXaI plasma concentration may harbor rare or
patient-specific SNVs that result in aberrant function or expression of their FXaI
metabolizing enzyme or transporter, consequently impacting their drug exposure.

38

39

1.9 References
1.

Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science
(New York, NY). 1964;145(3638):1310-2.

2.

Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its
function as a biochemical amplifier. Nature. 1964;202:498-9.

3.

Hoffman M, Monroe DM, 3rd. A cell-based model of hemostasis. Thrombosis and
haemostasis. 2001;85(6):958-65.

4.

Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue
factor and factor VII: additional pathway for initiating blood coagulation.
Proceedings of the National Academy of Sciences of the United States of America.
1977;74(12):5260-4.

5.

Gailani D, Broze GJ, Jr. Factor XI activation by thrombin and factor XIa. Seminars
in thrombosis and hemostasis. 1993;19(4):396-404.

6.

Wildgoose P, Kisiel W. Activation of human factor VII by factors IXa and Xa on
human bladder carcinoma cells. Blood. 1989;73(7):1888-95.

7.

Monkovic DD, Tracy PB. Functional characterization of human platelet-released
factor V and its activation by factor Xa and thrombin. The Journal of biological
chemistry. 1990;265(28):17132-40.

8.

Monroe DM, Hoffman M, Roberts HR. Transmission of a procoagulant signal from
tissue factor-bearing cell to platelets. Blood coagulation & fibrinolysis : an
international journal in haemostasis and thrombosis. 1996;7(4):459-64.

9.

Hultin MB. Modulation of thrombin-mediated activation of factor VIII:C by calcium
ions, phospholipid, and platelets. Blood. 1985;66(1):53-8.

10.

Bevers EM, Comfurius P, Zwaal RFA. Changes in membrane phospholipid
distribution during platelet activation. Biochimica et Biophysica Acta (BBA) Biomembranes. 1983;736(1):57-66.

11.

Mann K, Nesheim M, Church W, Haley P, Krishnaswamy S. Surface-dependent
reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76(1):1-16.

12.

Brotman DJ, Deitcher SR, Lip GY, Matzdorff AC. Virchow's triad revisited.
Southern medical journal. 2004;97(2):213-4.

13.

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor
for stroke: the Framingham Study. Stroke. 1991;22(8):983-8.

14.

Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al.
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010
Study. Circulation. 2014;129(8):837-47.

15.

Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation:
Virchow's triad revisited. Lancet (London, England). 2009;373(9658):155-66.

39

40

16.

Pollick C, Taylor D. Assessment of left atrial appendage function by transesophageal
echocardiography. Implications for the development of thrombus. Circulation.
1991;84(1):223-31.

17.

Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical
patients with atrial fibrillation. The Annals of thoracic surgery. 1996;61(2):755-9.

18.

Masawa N, Yoshida Y, Yamada T, Joshita T, Ooneda G. Diagnosis of cardiac
thrombosis in patients with atrial fibrillation in the absence of macroscopically
visible thrombi. Virchows Archiv A, Pathological anatomy and histopathology.
1993;422(1):67-71.

19.

Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, et al. Fibrosis in
left atrial tissue of patients with atrial fibrillation with and without underlying mitral
valve disease. Heart (British Cardiac Society). 2004;90(4):400-5.

20.

Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological
substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation.
1997;96(4):1180-4.

21.

Ohara K, Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, et al. Accumulation of
risk factors enhances the prothrombotic state in atrial fibrillation. International
journal of cardiology. 2008;126(3):316-21.

22.

Inoue H, Nozawa T, Okumura K, Jong-Dae L, Shimizu A, Yano K. Prothrombotic
activity is increased in patients with nonvalvular atrial fibrillation and risk factors for
embolism. Chest. 2004;126(3):687-92.

23.

Freestone B, Chong AY, Lim HS, Blann A, Lip GY. Angiogenic factors in atrial
fibrillation: a possible role in thrombogenesis? Annals of medicine. 2005;37(5):36572.

24.

Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor
and soluble p-selectin as indices of endothelial damage and platelet activation in 1321
patients with nonvalvular atrial fibrillation: relationship to stroke risk factors.
Circulation. 2002;106(15):1962-7.

25.

Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. Creactive protein elevation in patients with atrial arrhythmias: inflammatory
mechanisms and persistence of atrial fibrillation. Circulation. 2001;104(24):2886-91.

26.

Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma
levels of interleukin-6 and C-reactive protein in atrial fibrillation. American heart
journal. 2004;148(3):462-6.

27.

Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Is the
hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth
factor? Stroke. 2002;33(9):2187-91.

28.

Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M, et al. Effect of human
recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity.
Arteriosclerosis, thrombosis, and vascular biology. 1997;17(12):3399-405.

40

41

29.

Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein
induces human peripheral blood monocytes to synthesize tissue factor. Blood.
1993;82(2):513-20.

30.

Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral
anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th
ed: American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 Suppl):e44S-88S.

31.

Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, et al. 2016 Focused
Update of the Canadian Cardiovascular Society Guidelines for the Management of
Atrial Fibrillation. Canadian Journal of Cardiology.32(10):1170-85.

32.

Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian
Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and
systemic thromboembolism in atrial fibrillation and flutter. The Canadian journal of
cardiology. 2011;27(1):74-90.

33.

Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al.
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial
fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events
(ACTIVE W): a randomised controlled trial. Lancet (London, England).
2006;367(9526):1903-12.

34.

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation.
Analysis of pooled data from five randomized controlled trials. Archives of internal
medicine. 1994;154(13):1449-57.

35.

Mann KG. Thrombin generation in hemorrhage control and vascular occlusion.
Circulation. 2011;124(2):225-35.

36.

Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ.
Validation of clinical classification schemes for predicting stroke: results from the
National Registry of Atrial Fibrillation. Jama. 2001;285(22):2864-70.

37.

Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk
stratification for predicting stroke and thromboembolism in atrial fibrillation using a
novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest.
2010;137(2):263-72.

38.

Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, et al. 2016 Focused
Update of the Canadian Cardiovascular Society Guidelines for the Management of
Atrial Fibrillation. The Canadian journal of cardiology. 2016;32(10):1170-85.

39.

Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent
stroke in patients who have nonvalvular atrial fibrillation. Annals of internal
medicine. 2007;146(12):857-67.

40.

Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A
crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg
chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. The
EMBO Journal. 1989;8(11):3467-75.

41

42

41.

Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, et al.
Structure of human des(1-45) factor Xa at 2.2 A resolution. Journal of molecular
biology. 1993;232(3):947-66.

42.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med.
2011;365(11):981-92.

43.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.
Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med.
2009;361(12):1139-51.

44.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban
versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):88391.

45.

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et
al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. New England
Journal of Medicine. 2013;369(22):2093-104.

46.

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD,
et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin
in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet
(London, England). 2014;383(9921):955-62.

47.

Pradaxa® (dabigatran etexilate) 75 mg, 110 mg and 150 mg product monograph.
Boehringer Ingelheim 2016 [Available from: https://www.boehringeringelheim.ca/sites/ca/files/documents/pradaxapmen.pdf.

48.

Xarelto® (rivaroxaban) 10 mg, 15 mg and 20 mg product monograph. Bayer 2018
[Available from: https://www.bayer.ca/omr/online/xarelto-pm-en.pdf.

49.

Eliquis® (apixaban) 2.5 mg and 5 mg product monograph. Bristol-Myers Squibb
2018
[Available
from:
https://www.pfizer.ca/sites/g/files/g10045006/f/201803/ELIQUIS_PM_211430_26
Feb2018_marketed_E.pdf.

50.

Lixiana® (edoxaban) 15 mg, 30 mg and 60 mg product monograph. Daiichi Sankyo.
2017.

51.

Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, et al. Warfarin Sodium
versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis. New
England Journal of Medicine. 1979;301(16):855-8.

52.

Levine M, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy
for ischemic cerebral vascular disease. Stroke. 1986;17(1):111-6.

53.

Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of
oral anticoagulant therapy in the treatment of proximal-vein thrombosis. The New
England journal of medicine. 1982;307(27):1676-81.

54.

Hylek EM, Skates SJ, Sheehan MA, Singer DE. An Analysis of the Lowest
Effective Intensity of Prophylactic Anticoagulation for Patients with Nonrheumatic
Atrial Fibrillation. New England Journal of Medicine. 1996;335(8):540-6.
42

43

55.

Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R. Pharmacokinetics
and pharmacodynamics of the enantiomers of warfarin in man. Clinical
Pharmacology & Therapeutics. 1974;15(4):424-30.

56.

O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clinical
pharmacology and therapeutics. 1974;16(2):348-54.

57.

Coumadin® (warfarin) 1, 2, 2.5, 3, 4, 5, 6 and 10 mg product monograph. BristolMyers Squibb. 2017.

58.

Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacology &
therapeutics. 1997;73(1):67-74.

59.

Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.
Pharmacogenetics. 1994;4(1):39-42.

60.

Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of
human cytochrome P450 2C9: baculovirus-mediated expression, purification,
structural characterization, substrate stereoselectivity, and prochiral selectivity of the
wild-type and I359L mutant forms. Archives of biochemistry and biophysics.
1996;333(2):447-58.

61.

Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the
human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996;6(5):429-39.

62.

Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the
cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding
complications. Lancet (London, England). 1999;353(9154):717-9.

63.

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL,
Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulationrelated outcomes during warfarin therapy. Jama. 2002;287(13):1690-8.

64.

Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding
risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.
Genetics in medicine : official journal of the American College of Medical Genetics.
2005;7(2):97-104.

65.

Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American
College of Cardiology Foundation guide to warfarin therapy. Circulation.
2003;107(12):1692-711.

66.

Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the
gene for vitamin K epoxide reductase. Nature. 2004;427(6974):541-4.

67.

D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et
al. A polymorphism in the VKORC1 gene is associated with an interindividual
variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105(2):645-9.

68.

Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect
of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New
England journal of medicine. 2005;352(22):2285-93.

43

44

69.

Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel
functional VKORC1 promoter polymorphism is associated with inter-individual and
inter-ethnic differences in warfarin sensitivity. Human molecular genetics.
2005;14(13):1745-51.

70.

Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, et al.
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1)
genotypes as determinants of acenocoumarol sensitivity. Blood. 2005;106(1):13540.

71.

Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The
largest prospective warfarin-treated cohort supports genetic forecasting. Blood.
2009;113(4):784-92.

72.

Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of
pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
Clinical pharmacology and therapeutics. 2008;84(3):326-31.

73.

Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A
genome-wide scan for common genetic variants with a large influence on warfarin
maintenance dose. Blood. 2008;112(4):1022-7.

74.

Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A
genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as
principal genetic determinants of warfarin dose. PLoS genetics. 2009;5(3):e1000433.

75.

Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, LaRue S, et al. Prospective
evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose
regimen for initiation of therapy. Blood. 2011;118(11):3163-71.

76.

Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, et al. Dosing algorithm for
warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population:
comparison with other equations. Pharmacogenomics. 2008;9(2):169-78.

77.

Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A
Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. New England
Journal of Medicine. 2013;369(24):2283-93.

78.

Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, et al. A
Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and
Phenprocoumon. New England Journal of Medicine. 2013;369(24):2304-12.

79.

Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T,
et al. A Randomized Trial of Genotype-Guided Dosing of Warfarin. New England
Journal of Medicine. 2013;369(24):2294-303.

80.

Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, et al. Effect of
Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control
Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized
Clinical Trial. Jama. 2017;318(12):1115-24.

81.

Cavallari LH, Kittles RA, Perera MA. Genotype-guided dosing of vitamin K
antagonists. The New England journal of medicine. 2014;370(18):1763.

44

45

82.

Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, et al. The
missing association: sequencing-based discovery of novel SNPs in VKORC1 and
CYP2C9 that affect warfarin dose in African Americans. Clinical pharmacology and
therapeutics. 2011;89(3):408-15.

83.

Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R,
et al. Genetic variants associated with warfarin dose in African-American
individuals: a genome-wide association study. Lancet (London, England).
2013;382(9894):790-6.

84.

Wigle TJ, Jansen LE, Teft WA, Kim RB. Pharmacogenomics GuidedPersonalization of Warfarin and Tamoxifen. Journal of personalized medicine.
2017;7(4).

85.

Weitz JI, Semchuk W, Turpie AG, Fisher WD, Kong C, Ciaccia A, et al. Trends in
Prescribing Oral Anticoagulants in Canada, 2008-2014. Clin Ther.
2015;37(11):2506-14.e4.

86.

Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral
anticoagulants in UK primary care. British journal of clinical pharmacology.
2017;83(9):2096-106.

87.

Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety,
pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor
Xa inhibitor, in healthy subjects. British journal of clinical pharmacology.
2013;76(5):776-86.

88.

Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al.
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics,
pharmacodynamics and food effect in healthy subjects. British journal of clinical
pharmacology. 2013;75(2):476-87.

89.

Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety,
pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral,
direct factor Xa inhibitor. Clinical pharmacology and therapeutics. 2005;78(4):41221.

90.

Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety,
pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor
Xa inhibitor--after multiple dosing in healthy male subjects. European journal of
clinical pharmacology. 2005;61(12):873-80.

91.

Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR. Apixaban inhibition of factor
Xa: Microscopic rate constants and inhibition mechanism in purified protein systems
and in human plasma. Journal of enzyme inhibition and medicinal chemistry.
2011;26(4):514-26.

92.

Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, et
al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an
oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514-21.

45

46

93.

Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, et al. Apixaban, an oral,
direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and
antihemostatic studies. J Thromb Haemost. 2008;6(5):820-9.

94.

US Food and Drug Administration, Eliquis: Clinical Pharmacology &
Biopharmaceutical
Review(s).
2012
[Available
from:
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPh
armR.pdf.

95.

US Food and Drug Adminstration, Xarelto: Clinical Pharmacology &
Biopharmaceutical
Review(s).
2009
[Available
from:
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPh
armR.pdf.

96.

Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al.
Association between edoxaban dose, concentration, anti-Factor Xa activity, and
outcomes: an analysis of data from the randomised, double-blind ENGAGE AFTIMI 48 trial. Lancet (London, England). 2015.

97.

Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption
and pharmacokinetics of rivaroxaban. International journal of clinical pharmacology
and therapeutics. 2013;51(7):549-61.

98.

Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al. Effect of
Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor
Xa. American journal of cardiovascular drugs : drugs, devices, and other
interventions. 2016;16(2):119-27.

99.

He K, Luettgen JM, Zhang D, He B, Grace JE, Jr., Xin B, et al. Preclinical
pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor
Xa inhibitor. European journal of drug metabolism and pharmacokinetics.
2011;36(3):129-39.

100. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of
rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug
metabolism and disposition: the biological fate of chemicals. 2009;37(5):1056-64.
101. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban
metabolism and pharmacokinetics after oral administration to humans. Drug
metabolism and disposition: the biological fate of chemicals. 2009;37(1):74-81.
102. Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, et al. Comparative
metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug
metabolism and disposition: the biological fate of chemicals. 2009;37(8):1738-48.
103. Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban, an oral,
direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and
humans. Drug metabolism and disposition: the biological fate of chemicals.
2009;37(5):1046-55.
104. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CA, et al. In Vitro Assessment
of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome

46

47

P450 Phenotyping, Inhibition, and Induction Studies. Drug Metabolism and
Disposition. 2010;38(3):448-58.
105. Gong IY, Mansell SE, Kim RB. Absence of both MDR1 (ABCB1) and breast cancer
resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition
and central nervous system entry. Basic & clinical pharmacology & toxicology.
2013;112(3):164-70.
106. Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, et al. Characterization of efflux
transporters involved in distribution and disposition of apixaban. Drug Metabolism
and Disposition. 2013;41(4):827-35.
107. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of
renal impairment on the pharmacokinetics, pharmacodynamics and safety of
rivaroxaban, an oral, direct Factor Xa inhibitor. British journal of clinical
pharmacology. 2010;70(5):703-12.
108. Chang M, Yu Z, Shenker A, Wang J, Pursley J, Byon W, et al. Effect of renal
impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
Journal of clinical pharmacology. 2016;56(5):637-45.
109. Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, et al. Effects of age
and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
Clinical pharmacokinetics. 2015;54(6):651-62.
110. Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the
pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa
inhibitor. Journal of clinical pharmacology. 2013;53(3):249-55.
111. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of
extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and
tolerability of apixaban in healthy subjects. British journal of clinical pharmacology.
2013;76(6):908-16.
112. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence
on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban
(BAY 59-7939) in healthy subjects. Journal of clinical pharmacology.
2007;47(2):218-26.
113. Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of
ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor
Xa inhibitor. British journal of clinical pharmacology. 2015;79(5):838-46.
114. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that
share its elimination pathways: pharmacokinetic effects in healthy subjects. British
journal of clinical pharmacology. 2013;76(3):455-66.
115. Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, et al. Population
pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with
atrial fibrillation. British journal of clinical pharmacology. 2018.
116. Ueshima S, Hira D, Fujii R, Kimura Y, Tomitsuka C, Yamane T, et al. Impact of
ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of

47

48

apixaban in Japanese patients with atrial fibrillation. Pharmacogenetics and
genomics. 2017;27(9):329-36.
117. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial
sequencing and analysis of the human genome. Nature. 2001;409(6822):860-921.
118. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence
of the human genome. Science (New York, NY). 2001;291(5507):1304-51.
119. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, et al. The diploid genome
sequence of an individual human. PLoS biology. 2007;5(10):e254.
120. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP:
the NCBI database of genetic variation. Nucleic acids research. 2001;29(1):308-11.
121. Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its
contribution to complex traits. Nature reviews Genetics. 2009;10(4):241-51.
122. Relling MV, Evans WE.
2015;526(7573):343-50.

Pharmacogenomics

in

the

clinic.

Nature.

123. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLAB*5701 genotype is a major determinant of drug-induced liver injury due to
flucloxacillin. Nature genetics. 2009;41(7):816-9.
124. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic
variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature.
2009;461(7262):399-401.
125. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, et al. SLCO1B1
variants and statin-induced myopathy--a genomewide study. The New England
journal of medicine. 2008;359(8):789-99.
126. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al.
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and
clinical efficacy of clopidogrel therapy. Jama. 2009;302(8):849-57.
127. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating
inhibitors. Proceedings of the National Academy of Sciences of the United States of
America. 1977;74(12):5463-7.
128. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al. Targeted
capture and massively parallel sequencing of 12 human exomes. Nature.
2009;461(7261):272-6.
129. Nielsen R, Paul JS, Albrechtsen A, Song YS. Genotype and SNP calling from nextgeneration sequencing data. Nature reviews Genetics. 2011;12(6):443-51.
130. Mamanova L, Coffey AJ, Scott CE, Kozarewa I, Turner EH, Kumar A, et al. Targetenrichment strategies for next-generation sequencing. Nature methods.
2010;7(2):111-8.
131. Sagreiya H, Berube C, Wen A, Ramakrishnan R, Mir A, Hamilton A, et al. Extending
and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare
variants of CYP2C9. Pharmacogenetics and genomics. 2010;20(7):407-13.
48

49

132. Liu N, Irvin MR, Zhi D, Patki A, Beasley TM, Nickerson DA, et al. Influence of
common and rare genetic variation on warfarin dose among African-Americans and
European-Americans using the exome array. Pharmacogenomics. 2017;18(11):105973.
133. Ramsey LB, Bruun GH, Yang W, Trevino LR, Vattathil S, Scheet P, et al. Rare
versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate
disposition. Genome Res. 2012;22(1):1-8.

49

50

2

Specific Aims and Hypotheses
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2.1

Specific aim 1

1. To measure the extent of the variability in plasma apixaban and rivaroxaban
concentration within atrial fibrillation (AF) patients in a routine care setting.

Factor Xa inhibitors (FXaIs), rivaroxaban and apixaban, represent a new class of oral
anticoagulants that are widely prescribed as an alternative to warfarin therapy for stroke
prevention in patients with AF. An important advantage of these drugs is that routine
monitoring of anticoagulation response is not necessary. Nevertheless, because of their
mechanism of action a FXaI anticoagulation effect can be inferred based on the observed
plasma concentration, with prolonged periods of elevated FXaI concentration associated
with increased risk for major bleeding. Currently, there is a paucity of data relating to
observed interpatient variation in FXaI plasma concentrations in the post-market clinical
setting. Given that the patient population that take FXaIs in the post-market setting may
vary greatly with their co-morbidities and extensive co-medications from those within
clinical trials, the systemic FXaI exposures achieved in these individuals may vary greatly
as well.

We hypothesize that the variation in the apixaban and rivaroxaban concentration
within the routine care setting is greater than the variation observed during clinical
trials.

To test this hypothesis, we determined rivaroxaban and apixaban plasma concentrations in
a cohort of 243 AF patients during routine clinic visits. As described in Chapter 4, in our
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routine-care setting rivaroxaban and apixaban plasma concentrations tended to be more
variable than those observed in clinical trials. Approximately 12% of patients receiving
rivaroxaban and 13% of patients receiving apixaban exceeded the 95th percentile for the
predicted maximum FXaI plasma concentration (Cmax) observed in clinical trials. Overall,
identification of additional clinical and molecular determinants that more fully predict
patients at risk for excessively high or low FXaI concentrations may enable a more precise
FXaI dosing regimen for the individual patient.

2.2

Specific aim 2

1. To identify predictors of variability in FXaI plasma concentration among
apixaban-treated AF patients using clinical variables, common genetic variation,
and an endogenous biomarker for apixaban metabolism.

Apixaban undergoes multiple pathways of elimination that include both metabolism, and
excretion, though renal, intestinal, and biliary mechanisms (1, 2). Factors that influence
these elimination pathways such as renal function, age, sex, weight, and common genetic
polymorphisms have been demonstrated to alter the pharmacokinetics of apixaban in
subjects, and are predictive of systemic apixaban exposure (3-6). Similarly, identifying a
factor that can be used as a measure of apixaban metabolism (endogenous biomarker) may
serve as an additional predictor of variability in apixaban exposure, especially given that
roughly one third of orally administered apixaban is excreted from the body in metabolite
form. Hepatic and intestinal cytochrome P450 3A enzymes (CYP3A4/5) are responsible
for the phase I metabolism (oxidation) of apixaban (7, 8). In humans, 4βhydroxycholesterol (4β-OHC) is an endogenous oxysterol, present in the blood, that is
52
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created through the conversion of cholesterol by CYP3A enzymes (9), and is recognized
as an emerging biomarker of CYP3A activity. Therefore, by examining 4β-OHC as a
marker for apixaban metabolism, together with factors that are known to impact apixaban
exposure (renal function, age, sex, weight, and common genetic variation), we are likely
able to better explain the variation in concentration observed within our apixaban-treated
cohort.

We hypothesize that CYP3A activity, as measured by 4β-OHC concentration is a
predictor of apixaban plasma concentration, and together with known clinical and
genetic determinants of apixaban exposure will better explain interpatient variation
in FXaI concentration compared to clinical and genetic factors alone.

To test this hypothesis, we determined 4β-OHC plasma concentrations in 136 characterized
and genotyped AF patients. As described in Chapter Four, we found a weak but statistically
significant correlation between plasma concentrations of apixaban and 4β-OHC, with
higher 4β-OHC concentrations (higher CYP3A4 activity) associated with lower apixaban
concentrations. Regression analysis demonstrated that 4β-OHC concentration was an
independent predictor of apixaban concentration in our cohort, along with age, female,
serum creatinine, and amiodarone use. Weight, diltiazem use, as well as CYP3A4*22,
CYP3A5*3, ABCB1 c.3435C>T, or ABCG2 c.421C>A carrier status were not significant
predictors of apixaban plasma concentration in our cohort.
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2.3

Specific aim 3

1. To develop a targeted next generation sequencing (NGS) approach for the
detection of genetic variation in pharmacogenes pertinent to drug disposition and
response.
2. To apply this method for single nucleotide variant (SNV) discovery in a small
cohort of apixaban-treated AF patients with aberrantly high drug plasma
concentrations.

In Chapter Four, we noted that known common genetic variation in metabolizing enzymes
and efflux transporters (CYP3A4*22, CYP3A5*3, ABCB1 c.3435C>T, or ABCG2
c.421C>A) were not significant predictors of interpatient variation in apixaban
concentration within our AF cohort. Furthermore, a large proportion (~72%) of this
interpatient variation remained unaccounted for within our regression analysis. Therefore,
we proposed that rare or patient-specific single nucleotide variations (SNV) within certain
individuals are likely contributing to this unexplained variation. While previous
pharmacogenetic research has focused on evaluating common functional variation (minor
allele frequency, [MAF] >5%), more recent large-scale whole genome or exome
sequencing studies have revealed that humans harbor a large number of rare (MAF <1%),
potentially deleterious variants in many of these pharmacogenes (10, 11). Further studies
support that rare SNVs in drug processing or drug target genes significantly contribute to
interpatient differences in drug disposition and response beyond established common
genetic predictors as shown for CYP2C9 and warfarin dose requirement (12, 13) and
SLCO1B1 and methotrexate clearance and toxicity (14). Targeted next-generation
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sequencing (NGS) represents a new time- and cost-effective technology for detecting
common and rare genetic variation, allowing for DNA enrichment of entire exomes or
coding exons of select genes coupled with massive parallel sequencing of the enriched
product. Through the application of this method, particularly, in those apixaban-treated AF
subjects who demonstrated unexpectedly high drug plasma concentrations, we would be
able to better identify those individuals with rare or patient-specific SNVs that result in
aberrant function or expression of their CYP enzyme or transporter, consequently
impacting their apixaban exposure.

We hypothesize apixaban-treated AF subjects with aberrantly high apixaban plasma
concentrations harbor rare or patient-specific functional SNVs within genes involved
in the metabolism and transport of apixaban.

To test this hypothesis, we generated a custom panel of capture probes to enrich a target
sequence of 422 kb of coding region in 100 pharmacogenes, including seven genes that are
relevant to apixaban disposition. NGS was carried out in 245 subjects (n=48/245 validation
cohort; n = 12/245 apixaban-treated AF cohort). As described in Chapter five we generated
a sufficient depth-of-coverage (DOC) > 30 × for 97.4% of the target sequence, with a total
of 1089 variants detected in 245 subjects. Selected SNVs (32 common and 5 rare or novel)
identified through NGS were found to be concordant with TaqMan genotyping and Sanger
sequencing results. Importantly, 60% of total variants were rare or previously unreported,
with a greater proportion of rare or novel SNVs predicted to alter protein function
compared to common SNVs. Each subject carried at least one predicted functional variant
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on both alleles across our target sequence, and 161 subjects (66%) were homozygous
carriers for at least one clinically actionable variant. More specifically, of the apixabantreated AF subjects that were sequenced, our exploratory analysis did not reveal potentially
deleterious SNV(s) within the selected candidate genes that may further explain their
observed elevated apixaban plasma concentration.
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3.1 Introduction
Direct-acting oral anticoagulants (DOACs) that target key rate-limiting enzymes in the
coagulation cascade are rapidly replacing warfarin as therapeutic agents of choice for
stroke prevention in the setting of atrial fibrillation (AF), as well as prevention or treatment
of venous thromboembolism (1-8). A key perceived advantage associated with the use of
DOACs is the relative ease in dosing and no requirement for routine monitoring of
anticoagulation response, such as INR (9).
Rivaroxaban and apixaban, both Factor Xa (FXa) inhibitors, elicit their
pharmacological effect in a concentration-dependent manner (10-14). Preclinical studies
measuring isolated human FXa enzyme activity over varying drug concentrations
demonstrated an inhibitory effect proportional to spiked plasma drug concentrations (2,
15). During Phase I (in-human) studies, these findings translated into prolonged clotting
times, with the anticoagulation effect directly relating to plasma concentration (10-14). As
such, there is a particular concern for increased bleeding risk with higher plasma
concentrations which has spurred the development of reversing agent for use in the setting
of major bleeding events (16-18).
The European Medicines Agency (EMA) and US Federal Drug Administration (FDA),
have shown interest in defining an acceptable therapeutic index that is clinically impactful
and actionable (16, 18, 19). To address the gap in knowledge of DOAC drug concentrations
in patients during routine care, we aimed to assess DOAC concentrations in patients with
existing AF who were prescribed rivaroxaban or apixaban as a part of standard care.
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3.2 Materials and Methods
3.2.1

Study design and participants

This prospective cohort study was carried out at the London Health Sciences Center,
University Hospital in London, Ontario. Patients with existing atrial fibrillation (AF)
prescribed rivaroxaban or apixaban at Cardiology or Anticoagulation Clinics were invited
to participate. Inclusion and exclusion criteria are outlined in Figure 3-1. The study
protocol was approved by the Health Sciences Research Ethics Board of the University of
Western Ontario (London, Canada), and written informed consent was obtained. The study
was conducted over a 3-year period (February 2013 and January 2016).
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Figure 3-1. Patient flow diagram.
Enrolled patients must have been on the same dose for ≥ 4 days at the recommended dosing
cycle for rivaroxaban (once daily) and apixaban (twice daily), with only those samples
collected >2 (rivaroxaban) and >3 (apixaban) hours post dose to be considered in the drug
concentration analysis. Abbreviations: LHSC, London Health Sciences Center; Tmax =
time of maximum concentration.
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3.2.2

Clinical data collection

Patient age, sex, weight, and height was collected at the time of blood sampling, along with
their most recent serum creatinine concentration to the time of draw. Renal function is
known to have a greater effect on observed rivaroxaban plasma concentration when
compared to apixaban (20). Renal function was monitored by determining the estimated
creatinine clearance (eCrCl) using the Cockcroft-Gault formula. Rivaroxaban and apixaban
are both reported substrates of the drug efflux transporter P-glycoprotein (P-gp), and drug
metabolizing cytochrome P450 (CYP) enzyme CYP3A4 (21-24). Accordingly,
concomitant use of moderate (amiodarone, diltiazem, fluconazole, verapamil) to strong
(clarithromycin, ketoconazole, ritonavir) P-gp/CYP3A4 inhibitors(25), and P-gp/CYP3A4
inducers(25) (carbamazepine, phenytoin, phenobarbital rifampin) were documented at the
time of sampling.

3.2.3

Sample collection, processing, and storage

Blood samples were obtained from each patient while taking their prescribed dose of
rivaroxaban or apixaban. Date and time of last dose and blood collection was recorded and
time since last dose (hours) was subsequently calculated. Blood samples were immediately
placed at 4°C, prior to centrifugation at 2000 g for 10 minutes for plasma isolation. Plasma
samples were stored at -80°C until further analysis.
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3.2.4

Determination of rivaroxaban and apixaban plasma
concentration.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays for rivaroxaban
and apixaban were developed and validated using modified protocols (26, 27).
Rivaroxaban, rivaroxaban-D4, and apixaban were obtained from Toronto Research
Chemicals (Toronto, Canada) and dissolved in dimethyl sulfoxide at 1mg/ml. [13C, 2H7]Apixaban (Alsachim, Illkirch-Graffenstaden, France) was dissolved in methanol at
1mg/ml. Calibration standards (0, 5, 10, 25, 50, 100, 150, 250, 500, 750, 1000 ng/mL) and
quality controls (QCs) (25, 250, 1000 ng/ml) were prepared in drug-naïve, non-filtered (K2EDTA) human plasma (Bioreclamation IVT, Maryland, USA). QCs were used to calculate
the precision and accuracy of the assay according to standards of the FDA Bioanalytical
Method Validation for chromatography (28). Standard or QC plasma (100 µl), and patient
plasma (50 µl) were respectively dissolved in 300 µl and 150 µl of acetonitrile spiked with
rivaroxaban-D4 or [13C, 2H7]-apixaban as an internal standard. Samples were kept at
ambient temperature for 5 minutes followed by centrifugation at 13,500 rpm for 20 min at
4°C. A volume of 100 µl of the supernatant was subsequently diluted with 75 µl of 0.1%
formic acid in H2O and transferred to glass auto-sampler vials. Chromatographic separation
was performed using an Agilent1200 G1312 Binary Pump (Agilent Technologies, Santa
Clara, USA) and a Hypersil GOLDTM C18 (50mm x 3mm ID, 5 µm particle size) column
(Thermo Scientific, San Jose, USA), with an injection volume of 40 µl. Mobile phases used
for gradient elution were 0.1% formic acid in water and acetonitrile. The mass analysis
was performed on a TSQ Vantage triple-quadrupole mass spectrometer (Thermo
Scientific). The following mass transitions were monitored in positive mode for
quantification: apixaban, 460.1⟶ 443.3 m/z; [13C, 2H7]-apixaban, 468.1⟶ 451.4 m/z;
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rivaroxaban, 436.4⟶144.9 m/z; and rivaroxaban-D4, 440.8⟶144.9 m/z. Assay
performance across the 25, 250, and 1000 ng/ml QCs were as follows: inter-day bias
(accuracy) and precision were respectively less than or equal to 5.2% and 4.2% for
rivaroxaban, and 1.5% and 8.5% for apixaban; intra-day bias and precision were
respectively less than or equal to 5.3% and 3.5% for rivaroxaban, and 1.3% and 5.1% for
apixaban.

3.2.5

Reference rivaroxaban and apixaban clinical trials population
pharmacokinetics data.

To compare the distribution of measured single time-point plasma concentrations in
relation to clinical trials, rivaroxaban and apixaban treated AF population concentration
data were sourced from Girgis et al (29) and the Eliquis® (apixaban) product monograph
(30) respectively. Rivaroxaban measured concentrations were compared to the population
concentration-time profile sourced from Girgis et al (presented in Figure 3-2, as median
and 5th-95th percentile). Maximum and minimum concentration values were taken directly
from the concentration-time profile. This simulated concentration-time profile of the 20
mg once daily rivaroxaban dose was obtained through population pharmacokinetic
modelling of sparsely sampled plasma concentration data from phase III (ROCKET AF)
rivaroxaban-treated atrial fibrillation patients (29). For apixaban, there are currently no
available published pharmacokinetic data that describe the entire time course of apixaban
concentrations specific to atrial fibrillation patients. Therefore, measured concentrations
were compared in relation to the maximum (Cmax) and minimum (Cmin) plasma
concentration values over the dosing interval (presented in Figure 3-3, as median and 5th95th percentile) provided in the Eliquis® (apixaban) product monograph for nonvalvular
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atrial fibrillation patients prescribed apixaban 5 mg twice daily. Specifically, we assessed
whether the measured apixaban concentrations fell within the range of 41 ng/ml to 321
ng/ml, representing the lower limit for Cmin (5th percentile) to the upper limit for Cmax
(95th percentile) respectively (30).

3.2.6

Statistical analysis

Analysis was performed using the statistical software, SPSS (Armonk, USA) and
GraphPad Prism 6 (La Jolla, USA).

3.3 Results
3.3.1

Patient characteristics

We analyzed DOAC concentration data from 243 AF patients (rivaroxaban, n=94;
apixaban, n=149) with subject characteristics summarized in Table 3-1. Compared to
clinical trials, our cohort had a higher proportion of females as well as higher rates of
concomitant moderate P-gp/CYP3A4 inhibitor use (amiodarone, verapamil, diltiazem).
For apixaban, our cohort had a higher percentage of patients who were ≥75 years of age
when compared to patients enrolled in the ARISTOTLE and AVERROES clinical trials
(50.3% compared to 31.2% and 33.8%, respectively).
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Table 3-1. Study population characteristics in relation to published trials.
Current Study

Published Trials

Characteristic

ROCKET AF

ARISTOTLE

(5)

(31)

AVERROES(6)

Drug

Rivaroxaban

Apixaban

Rivaroxaban

Apixaban

Apixaban

Subjects, n

94

149

7131

9120

2808

Age, median (IQR) or mean (SD)

68 (60-78)

75 (66-82)

73 (65-78)

70 (63-76)

70 (9)

Age, ≥65 years, (%)

60.6

79.2

76.9 (32)

69.9 (33)

69.3

Age, ≥75 years, (%)

30.9

50.3

44.0 (34)

31.2

33.8

Sex, Female (%)

45.7

47.7

39.7

35.3

41.5

BMI, kg/m2, median (IQR) or mean

29 (24-34)

29 (25-34)

28 (25-32)

NR

28 (5)

Weight, kg, median (IQR)

82 (70-99)

83 (70-97)

NR

82 (70-95)

NR

CHADS2, mean (SD)

2.0 (1.3)

2.6 (1.3)

3.5 (1.0)

2.1 (1.1)

2.0 (1.1)

15 mg daily, (%)

25.5

-

20.7 (35)

-

-

20 mg daily, (%)

74.5

-

79.2 (35)

-

-

2.5 mg twice daily, (%)

-

38.3

-

4.7

6.4

5 mg twice daily, (%)

-

61.7

-

95.3

93.6

(SD)

Rivaroxaban Dose

Apixaban Dose
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Concomitant moderate P-gp and
CYP3A4 Inhibitor use, (%)

30.9

30.8

18.2 (36)

-

-

Amiodarone, (%)

11.3

13.4

NR

11.1

11.0

Diltiazem and Verapamil, (%)

19.6

17.4

NR

NR

9.0

5.2

2.8

NR

NR

NR

Phenobarbital, (%)

0.0

0.7

NR

NR

NR

Phenytoin, (%)

3.1

0.7

NR

NR

NR

Carbamazepine, (%)

2.1

0.7

NR

NR

NR

Rifampicin, (%)

0.0

0.7

NR

NR

NR

11.8 (2-23.5)

6.2 (3-11.9)

-

-

-

7111 (32)

9120 (33)

2798(33)

Concomitant P-gp and CYP3A4
Inducer use, (%)

Hours post dose, mean (min-max)
Renal function, creatinine clearance*
subjects, n

94

149

Normal (>80 ml/min), (%)

52.1

37.6

32.2 (32)

41.2 (33)

34.0 (33)

Mild (50-79 ml/min), (%)

24.5

32.9

46.6 (32)

41.9 (33)

38.2 (33)

Moderate (30-49 ml/min), (%)

17.0

21.5

21.0 (32)

15.0 (33)

17.5 (33)

Severe (15-30 ml/min), (%)

2.1

3.3

NR

1.5 (33)

2.0 (33)

Not Reported, (%)

4.3

4.7

0.2 (32)

0.4 (33)

8.3 (33)

84 (69-98)

91 (72-111)

NR

NR

NR

Serum Creatinine, µmol/L, median
(IQR)

Abbreviations: BMI, body mass index; IQR, interquartile range; NR, not reported; SD, standard deviation; Data represented as: percent
of cohort (%), median (IQR, 25th and 75th percentile), mean (±SD); *Creatinine clearance estimated using Cockcroft-Gault formula for
patients with available serum creatinine.
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3.3.2

Rivaroxaban plasma concentrations

We observed approximately 60-fold variation, based on minimum to maximum plasma
concentration across the dosing interval, in patients prescribed rivaroxaban 20 mg daily
(n=70) and 15 mg daily (n=24). When the observed concentrations in this cohort of patients
were plotted in relation to AF population concentration-time profiles assessed during
clinical trials (See Methods, for Figure 3-2 reference details)(29), 40.4% (n=38) of
rivaroxaban patient values were outside the predicted 5-95th population percentile for
concentrations (Figure 3-2). Of the 38 patients outside the predicted concentration range,
21 were above the 95th percentile while 17 were below the 5th percentile. Eleven (11.7%)
of measured concentrations across the dosing interval exceeded 363.9 ng/ml, which is the
estimated upper limit (95th percentile) of Cmax for an AF patient taking rivaroxaban 20
mg once daily at steady-state (29). Rivaroxaban plasma concentrations were also plotted
according to those above or below the estimated creatinine clearance threshold used for
dose selection (50 ml/min) (Figure 3-2B).
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Figure 3-2. Rivaroxaban plasma concentration in AF patients within routine care.
Observed plasma rivaroxaban concentration in relation to dose (A) and criteria required for
appropriate dosing: estimated creatinine clearance (B), superimposed on to clinical trial
pharmacokinetic population data for atrial fibrillation (AF) patients (See Methods).
Estimated creatinine clearance calculated using Cockcroft-Gault’s formula, patients
missing serum creatinine data were excluded (n=4, panel B). Abbreviations: Cmax
maximum concentration; Cmin, minimum concentration.
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3.3.3

Apixaban plasma concentrations

A 50-fold variation (minimum to maximum) was observed in measured plasma
concentrations for both apixaban dosing regimens: 5 mg twice daily (n = 92) or 2.5
mg twice daily (n = 57). Of the combined 149 patients, 24 (16.1%) attained
concentrations outside the maximum (Cmax, 95th percentile) and minimum (Cmin,
5th percentile) plasma concentration values reported in the Eliquis product
monograph for AF patients taking 5 mg twice daily (Figure 3-3A). More specifically,
19 versus 5 patients had concentrations above and below the reported Cmax and
Cmin, respectively.
The recommended apixaban dose for stroke prevention in AF patients is 5 mg
twice daily, or the reduced 2.5 mg twice daily dose in those fulfilling 2 of following
3 clinical criteria: age ≥ 80 years, serum creatinine ≥133 µmol/L, and weight ≤60 kg.
The observed apixaban concentrations were also plotted according to these clinical
criteria (Figure 3-3B-D). Plasma concentrations of patients taking 5 mg versus 2.5
mg twice daily (220.6 ng/ml compared to 173.3 ng/ml) were similar with only a
modest 1.27-fold difference between the mean measured apixaban concentrations.
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Figure 3-3. Apixaban plasma concentration in AF patients within routine care
Observed plasma apixaban concentration in relation to dose (A), and criteria required for
appropriate dosing: age (B), serum creatinine (C), and weight (D). Measured concentration
compared to predicted maximum (Cmax) and minimum (Cmin) plasma concentrations
values for 5 mg twice daily dose, as noted in the apixaban product monograph for atrial
fibrillation (AF) patients. Patients missing serum creatinine data were excluded (n=7, panel
C).
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3.3.4

Concomitant P-glycoprotein and CYP3A4 inhibitors and
inducers

Currently there are no recommendations regarding concomitant use of moderate Pgp/CYP3A4 inhibitors such as amiodarone and diltiazem. In our patients, these agents were
prescribed in 30% of our cohort. We compared DOAC plasma concentrations of
concomitant amiodarone and diltiazem users to non-users. There was a lack of relationship
between moderate inhibitor use and DOAC plasma concentrations, however, this study was
not well powered to determine the effect of moderate inhibitor use on DOAC plasma
concentrations. We were also unable to assess the effect of P-gp/CYP3A4 inducing
medications on DOAC concentrations as few patients were co-prescribed these
medications.

3.4 Discussion
3.4.1

Study Summary

This study examined the extent of interpatient variation in plasma DOAC concentrations
in AF patients in a routine clinical care setting, prescribed rivaroxaban or apixaban in
comparison to that observed in clinical trials. Plasma concentrations of both rivaroxaban
and apixaban exhibited marked interpatient variability in that 40% of rivaroxaban patients
were outside the 5-95th population percentile ranges for plasma concentrations observed in
clinical trials, of which 11.7% exceeded the upper limit (95th percentile) for Cmax (29).
Similarly for apixaban, 12.8% of our patients were above the 95th percentile for Cmax,
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whereas 3.4% were below the 5th percentile for Cmin, as outlined in the apixaban (Eliquis)
product monograph (30).

3.4.2

Potential clinical relevance of our findings

Currently, there are no approved blood tests for anticoagulation response to monitor DOAC
therapy. Although the attained plasma concentration of DOACs mirror their inhibitory
effects (whether thrombin or FXa) on their target (2, 10, 12, 15, 37, 38) the utility of a
pharmacokinetic-based approach to improving DOAC therapy is dependent on the
association between drug exposure and clinical response. The potential relationship
between FXa inhibitor circulating concentration and harm (major bleeding) versus efficacy
(stroke prevention in AF, venous thrombotic embolism (VTE) in total knee/hip
replacement) was noted in the FDA’s Clinical Pharmacology and Biopharmaceutics
Reviews documents (21, 39). In addition, there is sufficient evidence to suggest the use of
ketoconazole, a potent P-gp and CYP3A4 inhibitor, increases DOAC exposure by
approximately 2-fold (40, 41). Due to the associated increased bleeding risk, ketoconazole
is contraindicated in patients taking rivaroxaban or apixaban (30, 42).
However, at the present time, the precise DOAC concentration thresholds that
accurately predict for over- or under-anticoagulation have not been established. Additional
studies involving therapeutic drug monitoring (TDM) may help to establish a therapeutic
index. Ideally, such a therapeutic index will then define an optimal plasma concentration
range that provides greatest benefit, that of stroke prevention for AF patients, while
minimizing bleeding risk. We note for the latest DOAC to attain regulatory approval,
edoxaban, a detailed assessment of edoxaban exposure vs bleeding and stroke or systemic
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embolic event risk was published as part of the ENGAGE AF-TIMI 48 trial. Interestingly,
the slope for bleeding risk was steeper, relative to the slope for stroke prevention,
particularly when the trough concentration exceeded 100 ng/ml (43).

3.4.3

Limitations

This is an observational study of patients who were recruited during their routine care
visits. As such, this limits our ability to account for the effect of adherence as well as
inaccurate self-reporting of time of last-dose on the drug concentration. It remains possible
that unreported missed doses or drug intake without food (rivaroxaban only) may explain
some of the inter-patient variability especially in patients with very low plasma
concentrations. Finally, this study lacks adequate sample size to assess clinically relevant
outcomes, such as major bleeding, stroke, or death. Prospective studies in routine care
patients that focus on attained DOAC concentration in relation to outcomes are needed.
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3.4.4

Conclusion

In this study, we demonstrate variation in DOAC plasma concentrations in routine care are
greater than that observed in clinical trials. Therapeutic drug monitoring may be helpful in
DOAC dosing and selection for a subset of patients with variable renal function or
requiring concomitant medications that can alter DOAC disposition. Overall, DOACs
represent an important new class of medications which are widely prescribed as an
alternative to warfarin therapy, and increasingly recommended as the initial oral
anticoagulant in the setting of AF with risk factors for stroke (8). Additional research
focused on the association of clinical and genetic variables to DOAC concentration and
clinical outcomes are needed.
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4.1 Introduction
Factor Xa inhibitor, apixaban, belongs to an increasingly prescribed class of direct-acting
oral anticoagulants (1, 2) used for prevention of stroke (3-5), and venous
thromboembolisms (VTE) (6, 7). Under the setting of stroke prevention in patients with
atrial fibrillation (AF) the recommended dosage of apixaban is 5 mg taken orally twice
daily, or 2.5-mg twice daily dose for those fulfilling at least two of the following clinical
criteria: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 133 µmol/L (8).
Apixaban undergoes multiple pathways of elimination, which include: renal
excretion (renal clearance accounts for 27% of its total clearance (9)), metabolism, as well
as intestinal and biliary excretion (10, 11). Not surprisingly, factors that influence these
elimination pathways have been shown to alter the pharmacokinetics of apixaban in
subjects, and ultimately drug exposure (12, 13). For instance, individuals with impaired
renal function exhibit lowered total clearance of apixaban and increased drug exposure
such that subjects with mild, moderate, and severe renal impairment were associated with
~16%, ~29%, and ~44% higher area-underneath-the-curve (AUC) values based on
regression analysis, respectively (12). Additional factors such as age and sex have shown
to also influence the total clearance of apixaban, resulting in modest to low increases in
drug exposure for subjects ≥65 years (32% higher AUC compared to those aged 18-40
years) and females (15% higher AUC compared to males) (13), with a difference in renal
function between groups also thought to be contributing to these effects. More recently,
functional genetic polymorphisms within genes that code for proteins involved in the
transport (ATP binding cassette [ABC] G2 gene) and metabolism (cytochrome P450 [CYP]
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3A5 gene) of apixaban were shown to be associated with drug exposure, and altered
apixaban clearance (14, 15).
In terms of metabolism, apixaban is predominately hydroxylated by hepatic and
intestinal cytochrome P450 3A enzymes (CYP3A4/5) (16, 17). Concomitant use of potent
inhibitors and inducers of CYP3A4 such as ketoconazole and rifampin respectively, have
been shown to alter apixaban AUC up to 50% (9, 18). In humans, 4β-hydroxycholesterol
(4β-OHC) is an endogenous oxysterol that is created through the hydroxylation of
cholesterol by CYP3A4 (19, 20). Studies have demonstrated that changes in plasma 4βOHC concentrations correlate with changes in CYP3A4 activity driven by strong inducers
and inhibitors of the enzyme (21, 22). Additional research has shown weak but significant
correlation with other markers of CYP3A4 activity (midazolam (21, 23) and quinine/3hydroxyquinine (24)). As such, 4β-OHC concentration may serve as an additional predictor
of interindividual variability in apixaban exposure. However, to date, the relationship
between apixaban blood concentrations and endogenous markers of CYP3A activity
among patients taking apixaban, has not been determined. Accordingly, in this study we
examined plasma 4β-OHC concentration − an emerging biomarker of CYP3A activity −
as a predictor of apixaban plasma concentration within AF patients. Furthermore, we
examined 4β-OHC concentration in combination with factors that are known to impact
apixaban exposure such as renal function, age, sex, weight, and common genetic variation,
in an attempt to better explain the interindividual variation in FXaI concentration observed
within our apixaban-treated cohort.
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4.2 Methods
4.2.1

Subjects and sample collection

Study protocol was approved by the Research Ethics Board of the University of Western
Ontario (London, Canada), and written informed consent was obtained from study
participants. Our study cohort consisted of apixaban-treated atrial fibrillation patients
obtained from a hospital setting as previously described (25), with a blood sample collected
at steady-state during regular apixaban dosing intervals.

4.2.2

Clinical and apixaban pharmacokinetic data

Patient blood was taken at steady-state with the following data collected at the time of
draw: apixaban dosing regimen (2.5 or 5 mg twice daily), hours post-dose, age, sex, weight,
serum creatinine (µmol/L), estimated creatinine clearance (mL/min, calculated using
Cockcroft-Gault equation), concomitant medications. Serum creatinine data was missing
for 5 individuals. Single time point apixaban plasma concentrations used in this study were
obtained from our previously reported dataset (25).

4.2.3

Determination of 4β-hydroxycholesterol (4β-OHC) plasma
concentration

Picolinic acid derivatization and ultra-high-pressure liquid chromatography-tandem mass
spectrometry (UHPLC-MS/MS) assay were used for measuring 4β-hydroxycholesterol
(4β-OHC) as described by Honda et al. (26) with modifications. Both 4βhydroxycholesterol and 4β-hydroxycholesterol-d7 (internal standard) were obtained from
Avanti Polar Lipids (Alabaster, AL) and dissolved in methanol at 1 mg/mL. All other
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chemicals were obtained from Sigma-Aldrich (St. Louis, MO). Calibration standards of
4β-OHC (0, 5, 10, 20, 25, 30, 40, 50, 100, 200, 400, 800 ng/ml) were prepared in Krebs–
Henseleit bicarbonate buffer. Standard or plasma sample aliquots (50 µL) were saponified
using 500 µL of ethanolic KOH containing 4β-hydroxycholesterol-(d7) at 10 ng/mL on a
shaker for 1 hour. Water (150 µL) was added to samples then extracted twice in 750 µL of
hexane, with the organic layer collected and evaporated to dryness in a Savant SpeedVac
concentrator (Thermo Scientific). Afterwards, 170 µL of the following derivatization
reagents were added to each sample and incubated at 80˚C for 1 hour: 2-methyl-6nitrobenzoic anhydride (100 mg), 4-dimethylaminopyridine (30 mg), picolinic acid (80
mg), pyridine (1.5 µL), and trimethylamine (0.2 µL). Following the reaction, samples were
once more extracted in 1 mL of hexane, and the organic layer was evaporated at 80˚C to
dryness. Samples were reconstituted in 20 µL of NaCl dissolved in water (5 g/L) and 80
µL of acetonitrile, then 20 µL of the resulting mixture were injected into the UHPLCMS/MS system. Chromatographic separation was performed using an Agilent 1290
Infinity ultra–high pressure liquid chromatography system (Agilent Technologies, Santa
Clara, CA) and an Agilent Zorbax Eclipse Plus C18 column (100 × 2.1 mm, 1.8 µm).
Mobile phases used for gradient elution were 0.1% formic acid in water and 1:1 v/v
acetonitrile:methanol. The mass analysis was performed on a TSQ Quantum triplequadrupole mass spectrometer (Thermo Scientific), while the following mass transition
were monitored in positive mode for quantification: 4β-hydroxycholesterol, 635.4 → 146.5
m/z; 4β-hydroxycholesterol-d7, 642.4 → 146.5 m/z. Interday variability on 3 separate days
was 14.9%.
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4.2.4

Single nucleotide polymorphism genotyping

Genomic DNA was extracted from participant blood sample using the Gentra Puregene
Blood Kit (Qiagen, Alameda, CA). Genes encoding ABCB1, ABCG2, CYP3A4 and
CYP3A5, were assessed based on established associations to apixaban metabolism and
disposition (16, 17, 27), as well as 4β-OHC metabolism (CYP3A4 and CYP3A5 only) (24).
Accordingly, TaqMan allelic discrimination assays (Applied Biosystems, Foster City, CA)
were used to genotype patients for the following-reduced functional polymorphisms:
CYP3A4 C>T Intron 6 (*22, rs35599367) (28), CYP3A5 g.6986A>G (*3, rs776746) (29),
ABCB1 c.3435C>T (rs1045642), and ABCG2 c.421C>A (rs2231142). Hardy-Weinberg
equilibrium was tested using χ2 method in GraphPad Prism 6 (La Jolla, USA).

4.2.5

Data analysis

Nonparametic Spearman’s correlation tests were performed to assess apixaban association
with covariates 4β-OHC plasma concentrations, age, weight, estimated creatinine
clearance (as shown in Figure 4-1 and Figure 4-2). Differences in 4β-OHC with respect
to moderate CYP3A4 inhibitor use were assessed by Kruskal-Wallis multiple comparisons.
Significance was defined as two-tailed p ≤ 0.05.
Log (base 10)-transformed apixaban plasma concentration was used as the dependent
variable in our multivariable linear regression analysis. We included the following
independent variables: age, sex, weight, serum creatinine (µmol/L), 4β-hydroxycholesterol
(ng/ml), concomitant P-gp and CYP3A4 inhibitor use, transporter or enzyme
polymorphism, apixaban dosing regimen (2.5 or 5 mg twice daily), and hours post-dose.
Rows containing missing data were removed from the dataset, as were those patients who
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were prescribed verapamil since there were too few patients to properly estimate the effect
of this drug on apixaban concentration. This resulted in a dataset of 119 patients. We tested
different genetic models for each genetic polymorphism – dominant, co-dominant,
recessive, and additive models – and the model that best described the fit of apixaban
plasma concentration was selected. With the exception of the ABCB1 c.3435C>T
polymorphism, SNP genotypes were treated as binary variables (dominant model) with
those that were homozygous wildtype coded as 0, and those that were heterozygous or
homozygous variant coded as 1. ABCB1 c.3435C>T genotype was included as an additive
model with those that were homozygous wild type, heterozygous, and homozygous variant
coded as 0, 1, and 2, respectively. P-gp and CYP3A4 inhibitors, amiodarone and diltiazem
were tested as separate binary variables, coded as 0 for non-users and 1 for users. Given
that amiodarone and diltiazem use may have an effect on 4β-hydroxycholesterol
concentration these variables were analyzed in separate models. We first regressed log
(base 10) concentration onto dose, hours post-dose, age, sex, weight, serum creatinine, 4βhydroxycholesterol, and transporter or enzyme polymorphism. We repeated this with the
same independent variables substituting 4β-hydroxycholesterol for amiodarone and
diltiazem use. Two outliers were identified when examining the models’ residuals, the
models’ R2 value improved after removing these outliers from the analysis.
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4.3 Results
4.3.1

Study population characteristics and allele frequencies

We analyzed 4β-OHC plasma concentration data in 136 apixaban-treated AF patients with
previously measured apixaban plasma concentration data (25). See Table 4-1 for summary
of patient characteristics. Thirty-one percent of subjects were also on a P-gp and CYP3A4
moderate inhibitor. Genotype and allele frequencies for the investigated ABCB1, ABCG2,
CYP3A4, CYP3A5, polymorphisms are listed in Table 4-2 with all genotype frequencies
within Hardy-Weinberg equilibrium.

88

Table 4-1. Study population characteristics

Characteristic
Subjects, n

136

Age, median (IQR)

75 (65-82)

Sex, Female (%)

46.3

Weight, kg, median (IQR)

82.7 (69.6-97.3)

BMI, kg/m2, median (IQR)

29.4 (24.6-34.0)

Apixaban Dose
2.5 mg twice daily, (%)

53 (39.3)

5 mg twice daily, (%)

83 (61.5)

Hours post dose, mean (min-max)

6.4 (3-11.9)

Apixaban concentration, ng/ml, median (IQR)
Concomitant P-gp and CYP3A4 Inhibitor use, (%)

187.6 (139.8-248.4)
30.8

Amiodarone, (%)

13.4

Diltiazem and Verapamil, (%)

17.4

4β-hydroxycholesterol, ng/ml, median (IQR)
Serum Creatinine, µmol/L, median (IQR)

44.4 (28.8-71.1)
91 (72-111)

Creatinine Clearance, mL/min, median (IQR) ‡

62.5 (47.7-93.6)

Data represented as: percent of cohort (%), median (IQR, 25th and 75th percentile),
mean (±SD). Abbreviations: BMI, body mass index; Lean body weight, LBW; IQR,
interquartile range; SD, standard deviation. (‡) Creatinine clearance calculated using
Cockcroft-Gault’s formula for patients with available serum creatinine.
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Table 4-2. Allele frequencies for the ABCB1, ABCG2, CYP3A4, and CYP3A5
polymorphisms
Genotype

No. of
patients

ABCB1 c.3435C>T
C/C
C/T
T/T
ABCG2 c.421C>A
C/C
C/A
A/A
CYP3A4 *22
C/C
C/T
T/T
CYP3A5 *3
A/A
A/G
G/G

Genotype Allele
Frequency frequency

54.7%
25
65
37

0.197
0.512
0.291
12.8%

98
29
2

0.76
0.225
0.016
7.5%

109
17
1

0.858
0.134
0.008
94.6%

0
14
115
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0
0.109
0.891

4.3.2

4β-hydroxycholesterol plasma concentration

We observed a 38.3-fold variation (minimum to maximum) in the measured plasma 4βOHC concentrations of our AF patients, with median of 44.4 ng/ml (13.5 - 131.6, 5-95th
percentile). When comparing the 4β-OHC in relation to apixaban we found there was a
statistically significant (p = 0.016, r = -0.2063) weak inverse correlation between their
measured plasma concentrations (Figure 4-1A). Apixaban concentrations did not
significantly correlate (p = 0.2047) with 4β-OHC concentrations when they normalized to
total cholesterol (Figure 4-1B).
We also compared 4β-OHC concentrations of subjects that were taking moderate
CYP3A4 and P-gp inhibitors to non-users (Figure 4-1C). Those taking diltiazem had 40%
lower 4β-OHC concentrations compared to non-users (p < 0.0045), however, no significant
difference was observed for amiodarone users. We did not observe a statistically significant
difference in 4β-hydroxycholesterol plasma concentrations between wildtype and carriers
of CYP3A4*22 and CYP3A5*3 alleles (data not shown).
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Figure 4-1. Relationship between apixaban and 4β-hydroxycholesterol plasma
concentrations.
Association between apixaban (single time point) plasma concentrations with (A) 4β-OHC
and (B) cholesterol normalized ratio. (C) Mean (±SD) 4β-OHC plasma concentrations in
subjects taking concomittant CYP3A4 inhibitors compared to non-users. (D) Proposed
mechanism for a assiocation between 4β-OHC, apixaban, and exogenous CYP3A4
inhibitors. Abbreviations: 4β-OHC, 4β-hydroxycholesterol; r, Spearman correlation
coefficient; p, p-value.
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4.3.3

Apixaban plasma concentration

We assessed the correlation between apixaban plasma concentration and the clinical factors
used for dose selection. After normalizing for dosage, apixaban plasma concentrations
positively correlated with increasing age (r = 0.3455, p < 0.0001) and increasing serum
creatinine (r = 0.3416, p < 0.0001) (Figure 4-2A-B). While patients that weighed less
appeared to have higher drug concentrations, this was not statistically significant (Figure
4-2C). Furthermore, plasma concentrations were found to correlate more with CockcroftGault’s estimated creatinine clearance (r = -0.4984, p < 0.0001; Figure 4-3), a formula
used to estimate glomerular filtration rate using age, serum creatinine, weight, and sex.
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Figure 4-2. Relationship between and apixaban and clinical factors used for dose selection.
Dose-normalized apixaban (single time-point) plasma concentrations versus clinical factors used for apixaban dosing: (A) age, (B)
serum creatinine, (C) serum creatinine. Abbreviations: r, Spearman correlation coefficient; p, p-value.
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Figure 4-3. Relationship between apixaban and estimated creatinine clearance.
Dose-normalized apixaban (single time-point) plasma concentrations versus estimated
creatinine

clearance.

eCrCl

was

calculated

using

Cockcroft-Gault’s

formula.

Abbreviations: eCrCl, estimated creatinine clearance; r, Spearman correlation coefficient;
p, p-value.
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4.3.4

Multivariable linear regression analysis

Multivariable linear regression analysis was carried out to assess the relative contribution
of 4β-OHC as determinant of apixaban plasma concentration while controlling for clinical
variables (age, sex, weight, serum creatinine, apixaban dose, hours post dose) as well as
genetic polymorphisms in CYP3A4, CYP3A5, ABCB1, and ABCG2. Our regression
analysis indicated higher 4β-OHC concentrations were associated with lower apixaban
concentrations, even after controlling for these covariates (p = 0.001; Table 4-3). The
adjusted r2 value (percent explained) of the model was 0.279. Higher apixaban
concentrations were associated with increased age (p = <0.001), female sex (p = 0.014),
and elevated serum creatinine (p = <0.001). Hours post dose, weight, diltiazem use, as well
as CYP3A4*22, CYP3A5*3, ABCB1 c.3435C>T, or ABCG2 c.421C>A carrier status
were not significant predictors (p > 0.05) of apixaban plasma concentration in our cohort.
Ultimately, the addition of 4β-OHC as a variable increased the variation explained by 7.3%
(27.9% versus 20.6% total variation explained) compared to a model with only clinical and
genetic variables (Figure 4-4).
The effect of amiodarone and diltiazem use were assessed in a separate regression
model excluding 4β-OHC (Figure 4-4). The results of this analysis indicated amiodarone
use (p = 0.014) and by not diltiazem use to be associated with higher apixaban plasma
concentration (Appendix C). This model explained 23.5% of interpatient variation in
apixaban plasma concentration.
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Table 4-3. Multiple linear regression coefficients for apixaban plasma concentration
in atrial fibrillation patients (n = 119).
Predictor variable

B

95% CI

P-value

Dose

0.111

0.076, 0.146

<0.001

Hours post dose

-0.013

-0.031, 0.005

0.152

Age, years

0.007

0.003, 0.011

0.001

Sex, Female

0.092

0.019, 0.166

0.014

Weight, kg

-0.001

-0.003, 0.001

0.461

Serum creatinine, µmol/L

0.002

0.001, 0.003

<0.001

ABCB1 c.3435C>T , per allele

0.002

-0.046, 0.051

0.925

ABCG2 c.421C>A, 1 or 2 allele

0.068

-0.009, 0.145

0.083

CYP3A4*22, 1 or 2 allele

0.010

-0.084, 0.103

0.837

CYP3A5*3, 1 or 2 allele

0.016

-0.092, 0.124

0.771

4β-Hydroxycholesterol, ng/ml

-0.001

-0.002, -0.001

0.001

Adjusted R squared for model, 0.279
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Figure 4-4. Interpatient variation in apixaban plasma concentration explained by
clinical variables, genetic polymorphisms, and 4β-hydroxycholesterol
Nested model comparing the percent of interpatient variation in apixaban plasma
concentration explained with or without including 4β-Hydroxycholesterol. (‡) Model 1
including independent variables: dose, hours post dose, age, sex, weight, serum creatinine,
as well as CYP3A4, CYP3A5, ABCB1, and ABCG2 genotype.
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4.4 Discussion
Apixaban is primarily oxidized by CYP3A enzymes (14, 15). Accordingly we examined
plasma 4β-OHC concentration − an emerging biomarker of CYP3A activity − as a
predictor of interindividual variability in apixaban plasma concentration among AF
patients. We found a weak, but statistically significant correlation between plasma
concentrations of apixaban and 4β-OHC, with higher 4β-OHC concentrations (higher
CYP3A4 activity) associated with lower apixaban concentrations (Figure 4-1, Table 4-3).
Even though the majority of the interindividual variation in apixaban concentration
remained unexplained (~72%), including 4β-OHC along with clinical variables in our
multivariable linear regression analysis improved the variation explained by 7% (28%
versus 21%) (Figure 4-4), when compared to a model with clinical variables alone.
Interestingly, 4β-OHC:cholesterol (cholesterol normalized ratio) did not show any
statistically significant correlation with apixaban concentration.
4β-hydroxycholesterol (4β-OHC) is one of the dominate oxysterols present in the
human circulation at concentrations 103-104 times lower than total cholesterol with a
reported half-life ≥ 60 hours (30, 31). The role of CYP3A4 in the hydroxylation of
cholesterol to 4β-OHC was demonstrated in the early 2000s by Bodin and colleagues
through in vitro incubation of cholesterol with recombinant CYP enzymes (CYP3A4,
CYP1A2, CYP2C9, CYP2B6) (32). Among the enzymes tested, 4β-OHC formation was
found only with CYP3A4. This effort came after the discovery that patients taking
carbamazepine, phenytoin, and phenobarbital (strong inducers of CYP3A) experienced an
≥ 20-fold increase in plasma 4β-OHC concentration (32). Since then, many studies have
shown that changes in 4β-OHC correlate well with changes in CYP3A activity that are
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driven by strong CYP3A inducers (19, 23, 33-35) and inhibitors (35-37), with 4β-OHC
increasing and decreasing from baseline, respectively. In our study, subjects that were
taking the moderate inhibitor, diltiazem (n = 22), had significantly lower 4β-OHC
concentration (40% lower compared to non-users, n = 94). However, no difference was
seen in amiodarone users, which is consistent with diltiazem having greater evidence for a
CYP3A4 inhibitory effect compared to amiodarone (38, 39).
The evidence surrounding 4β-OHC supports its utility for assessing changes in the
CYP3A activity that are driven by strong CYP3A inhibitors and inducers. On the other
hand, its usefulness as a marker of basal CYP3A activity is yet to be fully established (40).
Current evidence shows a weak correlation between 4β-OHC concentrations and
previously recognized markers of CYP3A activity (midazolam (21, 23) and quinine/3hydroxyquinine (24)), but its association with other exogenous CYP3A substrates have
produced mixed results. In an study looking at anticancer drug, docetaxel (largely
metabolized by CYP3A4), the authors found 4β-OHC to have limited predictive value
towards docetaxel clearance, with a correlation between 4β-OHC concentration and
clearance seen only in males (r = .35, p = 0.01) (41). Our group has previously reported a
relationship between 4β-OHC and plasma concentrations of the lipid-lowering drug,
atorvastatin, also known to be metabolized by CYP3A4 (42). Taken together, the degree
of association between 4β-OHC and exogenous substrates is more than likely complicated
by factors other than CYP3A that include, but are not limited to: differences solubility and
permeability, intestinal versus hepatic metabolism, and substrate specificity to intestinal,
hepatic, or renal transporters.
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Although CYP3A-mediated metabolism is an elimination pathway for apixaban, it
is not the only way that this drug is cleared from the body. In a mass-balance study with
healthy subjects, only ~30% of the recovered apixaban dose (after oral administration) was
in metabolite form (10). This may reflect why 4β-OHC was observed to have a marginal
effect in explaining the variation of apixaban plasma concentration among our AF patients.
Kidney function and age were the strongest predictors of variation in apixaban
concentration among our AF cohort. The correlation of apixaban plasma concentration
with serum creatinine (Figure 4-2B, Table 4-3) and estimated creatinine clearance (Figure
4-3) that we observed is consistent with phase I study results, which showed worsening
renal impairment correlated with reduced total clearance and increased AUC. Furthermore,
our observation of higher apixaban concentration being associated with increased age
(Figure 4-2A, Table 4-3) and female sex (Table 4-3), were also consistent with previous
studies involving healthy (13), AF (14), and VTE (43) subjects. Although extremes in body
weight (≤ 50 kg or ≥120 kg) have previously been shown to influence apixaban exposure
(44), weight was not a predictor of variation in apixaban concentration among our patients.
This likely due to the fact that only 12% of our patients were ≤ 50 kg or ≥120 kg. In addition
to the CYP3A enzymes, apixaban is a known substrate of ATP binding cassette (ABC)
efflux transporters, P-glycoprotein (P-gp, ABCB1) and Breast Cancer Resistance Protein
(BCRP, ABCG2) (14, 15). While we did not observe an association between carrier status
of common functional genetic polymorphisms and variability in apixaban plasma
concentration, recent work in a Japanese AF population report the ABCG2 421A/A
genotype to be associated with higher trough apixaban plasma concentrations and reduced
clearance, whilst the CYP3A5*1/*1 genotype was seen to be associated with lower trough
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concentration and higher clearance (14, 15). This discrepancy is likely due to the
differences in the allele frequencies that are exist between the different ethnic populations
(Ueshima et al. allele frequencies were 33% and 78% for ABCG2 421C>A and CYP3A5*3
respectively). The effect of genetic variation may have been observed had there been more
variant carriers in our study.
In summary, our results are consistent with what is known about the CYP3A4mediated metabolism of apixaban and 4β-OHC formation. Even though the clinical factors
used for dose selection, such as age and serum creatinine, accounted for the majority of the
explainable variation in apixaban plasma concentration, our findings suggest that CYP3A4
activity can be used as an additional predictor of interindividual variability of apixaban
exposure. Indeed, further investigations correlating 4β-OHC as well as other markers of
CYP3A4 activity with parameters of apixaban exposure (i.e., AUC, trough plasma
concentrations) and clearance are warranted to confirm the degree to which CYP3A4
activity influences apixaban exposure.

102

4.5 References:
1.

Xu Y, Holbrook AM, Simpson CS, Dowlatshahi D, Johnson AP. Prescribing patterns
of novel oral anticoagulants following regulatory approval for atrial fibrillation in
Ontario, Canada: a population-based descriptive analysis. CMAJ Open.
2013;1(3):E115-E9.

2.

Weitz JI, Semchuk W, Turpie AG, Fisher WD, Kong C, Ciaccia A, et al. Trends in
Prescribing Oral Anticoagulants in Canada, 2008-2014. Clin Ther.
2015;37(11):2506-14.e4.

3.

Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, et al. 2016 Focused
Update of the Canadian Cardiovascular Society Guidelines for the Management of
Atrial Fibrillation. Canadian Journal of Cardiology.32(10):1170-85.

4.

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med.
2011;365(11):981-92.

5.

Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral
anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th
ed: American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 Suppl):e44S-88S.

6.

Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus
enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a
randomised double-blind trial. Lancet (London, England). 2010;375(9717):807-15.

7.

Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus
Enoxaparin for Thromboprophylaxis after Hip Replacement. New England Journal
of Medicine. 2010;363(26):2487-98.

8.

Eliquis® (apixaban) 2.5 mg and 5 mg product monograph. Bristol-Myers Squibb
2018
[Available
from:
https://www.pfizer.ca/sites/g/files/g10045006/f/201803/ELIQUIS_PM_211430_26
Feb2018_marketed_E.pdf.

9.

Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al. Effect of
Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor
Xa. American journal of cardiovascular drugs : drugs, devices, and other
interventions. 2016;16(2):119-27.

10.

Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban
metabolism and pharmacokinetics after oral administration to humans. Drug
metabolism and disposition: the biological fate of chemicals. 2009;37(1):74-81.

11.

Zhang D, Frost CE, He K, Rodrigues AD, Wang X, Wang L, et al. Investigating the
Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of
Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an
Intravenous Dose and Use of Drug Transporter Knockout Rats. Drug Metabolism
and Disposition. 2013;41(4):906-15.

103

12.

Chang M, Yu Z, Shenker A, Wang J, Pursley J, Byon W, et al. Effect of renal
impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
Journal of clinical pharmacology. 2016;56(5):637-45.

13.

Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, et al. Effects of age
and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
Clinical pharmacokinetics. 2015;54(6):651-62.

14.

Ueshima S, Hira D, Fujii R, Kimura Y, Tomitsuka C, Yamane T, et al. Impact of
ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of
apixaban in Japanese patients with atrial fibrillation. Pharmacogenetics and
genomics. 2017;27(9):329-36.

15.

Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, et al. Population
pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with
atrial fibrillation. British journal of clinical pharmacology. 2018.

16.

Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CA, et al. In Vitro Assessment
of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome
P450 Phenotyping, Inhibition, and Induction Studies. Drug Metabolism and
Disposition. 2010;38(3):448-58.

17.

Zhang D, He K, Herbst JJ, Kolb J, Shou W, Wang L, et al. Characterization of efflux
transporters involved in distribution and disposition of apixaban. Drug Metabolism
and Disposition. 2013;41(4):827-35.

18.

Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of
ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor
Xa inhibitor. British journal of clinical pharmacology. 2015;79(5):838-46.

19.

Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L.
4β-Hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability
and half-life of elimination after induction with rifampicin. British journal of clinical
pharmacology. 2009;67(1):38-43.

20.

Diczfalusy U, Nylen H, Elander P, Bertilsson L. 4beta-Hydroxycholesterol, an
endogenous marker of CYP3A4/5 activity in humans. British journal of clinical
pharmacology. 2011;71(2):183-9.

21.

Tomalik-Scharte D, Lutjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U. Plasma
4beta-hydroxycholesterol: an endogenous CYP3A metric? Clinical pharmacology
and therapeutics. 2009;86(2):147-53.

22.

Shin KH, Choi MH, Lim KS, Yu KS, Jang IJ, Cho JY. Evaluation of endogenous
metabolic markers of hepatic CYP3A activity using metabolic profiling and
midazolam clearance. Clinical pharmacology and therapeutics. 2013;94(5):601-9.

23.

Bjorkhem-Bergman L, Backstrom T, Nylen H, Ronquist-Nii Y, Bredberg E,
Andersson TB, et al. Comparison of endogenous 4beta-hydroxycholesterol with
midazolam as markers for CYP3A4 induction by rifampicin. Drug metabolism and
disposition: the biological fate of chemicals. 2013;41(8):1488-93.

104

24.

Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, et al. 4Betahydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5
genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.
Pharmacogenetics and genomics. 2008;18(3):201-8.

25.

Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes AC, Alfonsi JE, et al. Interpatient
Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. The
Canadian journal of cardiology. 2017;33(8):1036-43.

26.

Honda A, Yamashita K, Hara T, Ikegami T, Miyazaki T, Shirai M, et al. Highly
sensitive quantification of key regulatory oxysterols in biological samples by LCESI-MS/MS. Journal of lipid research. 2009;50(2):350-7.

27.

Gong IY, Mansell SE, Kim RB. Absence of both MDR1 (ABCB1) and breast cancer
resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition
and central nervous system entry. Basic & clinical pharmacology & toxicology.
2013;112(3):164-70.

28.

Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in
CYP3A4 affects hepatic expression and response to statin drugs. The
pharmacogenomics journal. 2011;11(4):274-86.

29.

Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in
CYP3A5 and its possible consequences. Pharmacogenomics. 2004;5(3):243-72.

30.

Breuer O. Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat
liver and human plasma. Journal of lipid research. 1995;36(11):2275-81.

31.

Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, et al. Metabolism
of 4 beta -hydroxycholesterol in humans. The Journal of biological chemistry.
2002;277(35):31534-40.

32.

Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, et al.
Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans:
evidence for involvement of cytochrome p450 3A4. The Journal of biological
chemistry. 2001;276(42):38685-9.

33.

Wide K, Larsson H, Bertilsson L, Diczfalusy U. Time course of the increase in 4betahydroxycholesterol concentration during carbamazepine treatment of paediatric
patients with epilepsy. British journal of clinical pharmacology. 2008;65(5):708-15.

34.

Kanebratt KP, Diczfalusy U, Backstrom T, Sparve E, Bredberg E, Bottiger Y, et al.
Cytochrome P450 induction by rifampicin in healthy subjects: determination using
the Karolinska cocktail and the endogenous CYP3A4 marker 4betahydroxycholesterol. Clinical pharmacology and therapeutics. 2008;84(5):589-94.

35.

Kasichayanula S, Boulton DW, Luo WL, Rodrigues AD, Yang Z, Goodenough A, et
al. Validation of 4beta-hydroxycholesterol and evaluation of other endogenous
biomarkers for the assessment of CYP3A activity in healthy subjects. British journal
of clinical pharmacology. 2014;78(5):1122-34.

36.

Lutjohann D, Marinova M, Schneider B, Oldenburg J, von Bergmann K, Bieber T,
et al. 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects

105

of itraconazole in man. International journal of clinical pharmacology and
therapeutics. 2009;47(12):709-15.
37.

Josephson F, Bertilsson L, Bottiger Y, Flamholc L, Gisslen M, Ormaasen V, et al.
CYP3A induction and inhibition by different antiretroviral regimens reflected by
changes in plasma 4beta-hydroxycholesterol levels. European journal of clinical
pharmacology. 2008;64(8):775-81.

38.

Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory
effects of amiodarone and its N-deethylated metabolite on human cytochrome P450
activities: prediction of in vivo drug interactions. British journal of clinical
pharmacology. 2000;49(3):244-53.

39.

Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD. Diltiazem
inhibition of cytochrome P-450 3A activity is due to metabolite intermediate
complex formation. The Journal of pharmacology and experimental therapeutics.
1999;290(3):1116-25.

40.

Mao J, Martin I, McLeod J, Nolan G, van Horn R, Vourvahis M, et al. Perspective:
4beta-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.
Drug metabolism reviews. 2017;49(1):18-34.

41.

de Graan AJM, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer
EAC, et al. 4β-hydroxycholesterol as an endogenous CYP3A marker in cancer
patients treated with taxanes. British journal of clinical pharmacology.
2015;80(3):560-8.

42.

DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, Suskin N, et al.
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin
concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6(4):400-8.

43.

Byon W, Sweeney K, Frost C, Boyd RA. Population Pharmacokinetics,
Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in
Subjects Treated for Venous Thromboembolism. CPT: pharmacometrics & systems
pharmacology. 2017;6(5):340-9.

44.

Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of
extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and
tolerability of apixaban in healthy subjects. British journal of clinical pharmacology.
2013;76(6):908-16.

106

5

Identification of rare or patient-specific single
nucleotide variants as potential determinants of
apixaban disposition using a custom targeted
next-generation exome sequencing approach

Gulilat M, Lamb T, Teft WA, Robinson JF, Tirona RG, Hegele RA, Kim RB, Schwarz UI.
Targeted next generation sequencing as a tool for precision medicine. Manuscript in
preparation, 2018.

107

5.1

Introduction

In Chapter Four, we noted that known common genetic variation in metabolizing enzymes
and efflux transporters (CYP3A4*22, CYP3A5*3, ABCB1 c.3435C>T, or ABCG2
c.421C>A) were not significant predictors of the interpatient variation in apixaban
concentration observed in our AF cohort. Furthermore, a large proportion (~72%) of this
variation remained unaccounted for within our regression analysis. It is our hypothesis that
rare or patient-specific single nucleotide variations within certain individuals are likely
contributing to this variability.
While previous pharmacogenetic research has focused on evaluating common
functional variation, more recent large-scale whole genome or exome sequencing studies
have revealed that humans harbor a large number of rare, potentially deleterious variants
in many of these pharmacogenes (1, 2). Specifically, the analysis of sequencing data for
146 pharmacogenes combining about 7500 individuals of the Exome Sequencing Project
(ESP) (3) and the 1000 Genomes Project (1000G) (4) indicated that more than 90% of all
recorded single nucleotide variants (SNVs) were rare with a minor allele frequency (MAF)
below 1%, and that 30-40% of the predicted functional variability was associated with
these rare variants (1). Further studies also support that rare SNVs in drug processing or
drug target genes significantly contribute to interpatient differences in drug disposition and
response beyond established common genetic predictors as shown for CYP2C9 and
warfarin dose requirement (5, 6) and SLCO1B1 and methotrexate clearance and toxicity
(7).
Targeted next-generation sequencing (NGS) represents a new time- and costeffective technology for detecting common and rare genetic variation, allowing for DNA
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enrichment of entire exomes or coding exons of select genes coupled with massive parallel
sequencing of the enriched product. Through the application of this method, particularly,
in those apixaban-treated AF subjects who demonstrated unexpectedly high drug plasma
concentrations, we would be able to better identify those individuals with rare SNVs that
result in aberrant function or expression of their CYP enzyme or transporter, consequently
impacting their apixaban exposure.
Therefore, we created a NGS-based exome capture panel (PGxSeq) capable of
detecting common and clinically established, as well as rare and potentially functional
genetic variation within 100 pharmacogenes, including seven genes (ABCB1, ABCG2,
CYP3A4, CYP3A5, POR, NR1H4, NR1I2) that are relevant to apixaban disposition. Our
objectives were to: 1) evaluate the sequencing performance as well as the accuracy of
variant discovery within a validation cohort (n = 48); 2) evaluate the identified variation in
all 100 pharmacogenes with respect to population allele frequencies and predicted
functional effects for a larger cohort (n = 245); 3) apply this method for SNV discovery in
a small exploratory cohort of apixaban-treated AF patients who exhibited FXaI plasma
concentrations exceeding the maximum concentration observed during clinical trials while
being dosed according to product monograph (test group n = 6, control n = 6).

5.2

Methods

A flow diagram of the sample and data processing can be found in Figure 5-1. A detailed
methods description can be found in Appendix D.
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Figure 5-1. Sample and data processing workflow. ‡
One subject was sequenced twice to obtain higher sample depth-of-coverage.
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5.2.1

Study population

NGS was carried out in a total of 245 Caucasian subjects, for which genomic DNA was
obtained from a venous blood sample following written informed consent. Sequencing
performance and accuracy of variant detection was evaluated in the first 48 subjects − this
was our validation cohort. Following this, all 245 subjects were used to evaluate genetic
variation in terms of population allele frequencies and predicted functional effect. Then we
carried out candidate gene SNV discovery in a subgroup of 12 apixaban-treated AF patients
(described below) with a known apixaban drug concentration phenotype. This study was
approved by the Research Ethics Board of Western University, London, Canada.

5.2.2

Apixaban cohort

Twelve individuals from this previous study were included as part of the n = 245
participants sequenced in this study, and consisted of two different apixaban plasma
concentration phenotypes: high concentration (test group, n = 6) and normal concentration
(control group, n = 6). Specifically, apixaban phenotype was determined based on whether
the patient’s measured apixaban plasma concentration fell within the range of 41 - 321
ng/mL, representing the lower limit for Cmin (5th percentile) to the upper limit for Cmax (95th
percentile), respectively, for an individual on apixaban 5 mg twice daily at steady state as
previously described (refer to Chapter Four). Concentrations above this range were
considered high, while those within were considered normal. The inclusion criteria for both
groups was that patients were dosed according to product monograph, and did not meet
any of the clinical factors used for dose reduction that are known clinical predictors of
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higher apixaban exposure (age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 133
µmol/L)(8).
Our goal was to discover rare or patient specific hypothesis generating single
nucleotide variations among candidate genes involved in the metabolism or transport of
apixaban that potentially correlate with apixaban concentration phenotype. The candidate
genes analyzed were selected based on the following evidence: 1) the gene product
interacts directly with apixaban as a transporter (ABCB1, ABCG2) or metabolizing enzyme
(CYP3A4, CYP3A5); or 2) the gene product is involved in regulating the expression
(NR1H4, NR1I2), or is required for the function (POR) of an enzyme or transporter that
interacts directly with apixaban.

5.2.3

Gene selection, capture probe design and enrichment
method

DNA enrichment was carried out using the Nextera Rapid Capture Custom Enrichment Kit
(Illumina, San Diego, CA) comprising of 100 genes including major cytochrome P450
(CYP) enzymes, phase II conjugation enzymes, drug transporters of the solute carrier
(SLC) and ATP binding cassette (ABC) families as well as regulatory proteins. In addition,
regions encompassing 14 known functional promoter or intronic SNVs were included.
Capture probes were custom-designed using the Illumina Design Studio (Illumina, San
Diego, CA) comprising of 722 kilobases (kb) with 4% overlap. DNA library preparation
and target-capture sequencing was conducted at the London Regional Genomics Center,
London, Ontario, as previously described (9).
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5.2.4

Base calling, sequence alignment, coverage analysis and
variant detection

Alignment of sequencing reads and variant calling were performed using the CLC Bio
Genomics Workbench 7.0 (CLC Bio, Aarhus, Denmark) through a custom-automated
workflow. Coverage analysis in the validation cohort and variant detection in all 245
subjects was restricted to coding regions plus 10-bp before and after each exon and 250-bp
of 5’ and 3’ UTR, and targeted promoter or intronic SNVs.

5.2.5

Variant annotation and in silico prediction

Functional annotation of SNVs was carried out using ANNOVAR (10) through in silico
prediction algorithms (Combined Annotation Dependent Depletion [CADD] (11), Sorting
Intolerant from Tolerant [SIFT] (12), and PolyPhen-2 (13)), and population frequency
determined through linkage with genomic databases (RefSeq, dbSNP137, 1000G, Exome
Aggregation Consortium [ExAC]; obtained July 8, 2015). Potentially functional SNVs (or
deleterious) were considered with a score of >20 for CADD (scaled) (11), <0.05 for SIFT
(12), or >0.85 for PolyPhen-2 (13). Variants were classified as non-synonymous,
synonymous, insertion or deletion (in-del; frameshift, non-frameshift), splicing, stop gain
or loss, or known functional intronic/ promoter variants as non-coding. Coding variants
were further grouped by MAF reported in the ExAC database as common (MAF ≥ 5%),
low frequency (1% ≤ MAF > 5%), or the combined category of rare (MAF < 1%) and novel
(absent from ExAC and dbSNP137). In silico functional assessment was restricted to
protein-coding and gain- or loss-of-a-stop codon SNVs.
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5.2.6

Concordance assessment

In our validation cohort, orthogonal genotyping was performed using TaqMan allelic
discrimination for 32 functionally validated or clinically actionable SNVs. Rare NGS
variants were confirmed retrospectively by Sanger sequencing within 4 pharmacogenes.
Sanger sequencing methods and TaqMan assay IDs are listed in Table S2, Appendix D,
and Table S3, Appendix D, respectively.

5.2.7

Statistical analysis

Analyses were performed using R (14) and GraphPad Prism 6 (La Jolla, USA). Differences
in the proportion of possibly deleterious variants grouped by frequency was assessed using
Chi-squared test, and Pearson correlation coefficient used to determine the association
between allele frequencies in our study compared to 1000 Genomes and ExAC database.
Statistical significance was defined as P<0.05.
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5.3
5.3.1

Results
Sequencing performance and accuracy of variant detection
in the validation cohort

Performance parameters by sequencing run for the first 48 subjects are presented in Table
5-1. The total number of sequenced reads per run ranged from 20.0 to 27.6M reads, with
87.1 to 89.2% of reads passing Illumina control filters (Reads PF). The mean per base
quality score (Phred quality score, Q) for Reads PF were ≥30, indicating a miscall error
rate in base calling of less than 0.1% (or 99.9% sequencing accuracy) up until the 150 bp
read position. A decline in base quality was observed beyond 150 bp likely due to a
combination of short fragment length with the 2 x 300 bp chemistry used for DNA library
preparations (Figure S1, Appendix E). Consequently, the threshold for variant detection
was set to Q ≥ 30 to minimize false-positive variant calls. After de-clustering each run,
sequencing data for each sample were assessed for read count, base quality, and guanine
(G) and cysteine (C) distribution (Figure 5-1). Three samples had a mean GC content of
up to 65%, exceeding the expected range of 45-50% (15) (Figure S2, Appendix E).
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Table 5-1. Overview of sequencing performance parameters in our validation cohort
separated by run cluster.
Run 1

Run 2

Run 3

Subjects, n

12

12

24

Cluster density, (1000/mm2)

841

1149

1183

Total reads, (106)

20

27.1

27.6

Reads PF, (106)

17.8

23.9

24

Reads PF, (%)

89.2

88.2

87.1

12

12

24

1.2

1.6

1

187.3 ª

297.7 ª

127.9 ª

DOC, median (- duplicates removed)

187 ª

303 ª

126 ª

Bases with mean DOC <30x, (%)

2.4 ᵇ

1.8 ᵇ

3.3 ᵇ

Raw sequencing parameters (n = 48)

Mapping parameters (422 kb)
Subjects, n
Reads PF mapped to hg19 genome (106)
per sample
DOC, mean (- duplicates removed)

Reads PF, reads passed filter; DOC, depth of coverage. ª Calculated for samples
across the 422 kb target sequence; ᵇ Calculated as percent of 422 kb target
sequence. ‡ Excluding one sample with low read count (< 2500 reads).
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We next assessed the depth-of-coverage (DOC), defined as the number of overlapping nonduplicate reads mapped to the reference genome, across the target sequence separated by
sequencing cluster (n = 12 or 24). As expected, samples in the smaller cluster had a greater
mean DOC per subject (range 183 – 298×) compared to those sequenced in the larger 24
DNA sample cluster (128×) (Table 5-1). Despite these differences, the percent bases with
a mean DOC < 30× was comparable ranging from 1.8% - 3.3%. When evaluated on a geneby-gene basis (Figure 5-2), 98 of the 100 genes on our panel had a mean DOC ≥ 80×.
Among all genes, the glutathione S-transferase (GST) genes showed the lowest DOC per
subject (min-max; 14.1 - 233× for GSTM1; 5.5 - 267× for GSTT1). Carboxylesterase 1
(CES1) had the highest proportion of targeted regions < 30×, largely due to lack of
coverage for exons 12 to 14, followed by carbonyl reductase 3 (CBR3), and CYP1A2
(Figure S3, Appendix E). The remaining genes of Phase I and II enzymes, ABC and SLC
transporters, nuclear receptors, and drug targets had ≥ 95% of their target region at DOC >
30×. Intra-subject variability in DOC was greatest in the 3 DNA samples with high GC
content (Figure S4, Appendix E).
Utilizing TaqMan assays for 32 validated or clinically actionable SNVs in our
validation cohort (Table 5-2.), we observed 100% concordant between TaqMan derived
versus NGS derived genotypes, confirming heterozygous and homozygous carrier status.
Using Saner sequencing we were able to confirm all five rare coding variants that were
identified by NGS (Table 5-2.).
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Transporter
ABC family
Transporter
SLC family
Nuclear receptors

shown as mean ±SD
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Figure 5-2. Depth of coverage per gene.

Depth-of-coverage (DOC) by gene separated by size of sequence cluster (n=12 or 24). ‡ For UGT1A4, UGT1A6, UGT1A8, and

UGT1A9, the first exon was included to calculate DOC while shared exons were assessed only once with UGT1A1. Data are

Table 5-2. Concordance rate (%) of genotypes between NGS data and TaqMan or Sanger validated genotypes in the
validation cohort (n = 48).
Gene

Allele

Polymorphism

Effect/
Location

dbSNP137

Study
1000G
(n=245)
EUR
AF
AF
A. Concordance of common and/or clinically relevant SNPs with TaqMan genotyping

EXaC
AF

Patients
tested
HET HOM

Concordance
(%)ª

ABCB1

c.3435 C>T

p.I1145I

rs1045642

0.47

0.47

0.50

11

3

100

ABCC2

c.1249 G>A

p.V417I

rs2273697

0.18

0.20

0.20

5

2

100

ABCG2

c.421 C>A

p.Q141K

rs2231142

0.11

0.10

0.12

10

3

100

ABCG2

c.34 G>A

p.V12M

rs2231137

0.04

0.06

0.11

2

-

100

CYP2B6

c.1459 C>T

p.R487C

rs3211371

0.12

0.10

0.09

8

1

100

CYP2B6

*9

c.516 G>T

p.Q172H

rs3745274

0.22

0.23

0.27

5

2

100

CYP2C19

*17

c.-806 C>T

promoter

rs12248560

0.22

0.23

NA

8

3

100

CYP2C19

*2

c.681 G>A

p.P227P

rs4244285

0.14

0.15

0.19

4

1

100

CYP2C9

*2

c.430 C>T

p.R144C

rs1799853

0.13

0.12

0.09

7

2

100

CYP2C9

*3

c.1075A>C

p.I359L

rs1057910

0.06

0.06

0.06

5

-

100

CYP2D6

*3A

g.2549 A>del

p.R208fs

rs35742686

0.03

0.02

0.01

2

-

100
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CYP2D6

*4

g.1846 G>A

splice

rs3892097

0.19

0.19

0.17

16

4

100

CYP2D6

*9

c.688_690AAG>del p.K281del rs5030656

0.02

0.02

0.02

1

-

100

CYP2D6

*10

g.100 C>T

p.P34P

rs1065852

0.22

0.20

0.25

18

4

100

CYP2D6

*41

g.2988 G>A

intronic

rs28371725

0.12

0.09

0.08

10

1

100

CYP3A4

*22

c.522-191 C>T

intronic

rs35599367

0.05

0.05

NA

7

-

100

CYP3A5

*3

g.6986 A>G

splice

rs776746

0.06

0.95

NA

6

-

100

CYP4F2

*3

c.1297 C>T

p.V433M

rs2108622

0.30

0.27

0.27

6

3

100

DPYD

c.2846 A>T

p.D949V

rs67376798

0.02

0.0022

0.0026

1

-

100

NR1H4/FXR

c.-1 G>T

5' UTR

rs56163822

0.03

0.02

0.08

4

-

100

NR1H3/LXRɑ

c.297 C>T

p.S547S

rs2279238

0.16

0.16

0.25

6

2

100

POR

c.1508 C>T

p.A503V

rs1057868

0.26

0.30

0.36

5

2

100

NR1I2/PXR

g.39823 C>T

intronic

rs2276707

0.20

0.17

0.24

9

-

100

SLCO1B1

*1b

c.388 A>G

p.N130D

rs2306283

0.39

0.40

0.48

9

4

100

SLCO1B1

*5

c.521 T>C

p.V174A

rs4149056

0.17

0.17

0.13

9

2

100

c.699 G>A

p.M233I

rs7311358

0.80

0.85

0.80

5

16

100

SLCO1B3
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SLCO2B1

c.935 G>A

p.R290Q

rs12422149

0.07

0.10

0.17

7

-

100

TPMT

*3A

c.460 G>A

p.A154T

rs1800460

0.04

0.03

0.03

4

-

100

TPMT

*3B

c.719 A>G

p.Y240C

rs1142345

0.04

0.03

0.04

4

-

100

VDR

g.1270 G>A

intergenic

rs11568820

0.17

0.23

NA

3

1

100

VDR

g.47906043 T>C

intergenic

rs4516035

0.43

0.43

NA

8

7

100

VKORC1

c.-1639 G>A

intergenic

rs9923231

0.39

0.40

NA

5

6

100

1

-

100

B. Concordance of rare variation in select genes by Sanger sequencing
ABCB1

c.3320 A>C

p.Q1107P

rs55852620

0.012

1.0E-02 6.1E-03

CYP2D6

c.A818C

p.H273P

rs5030867

0.002

NA

0.0013

1

-

100

SLCO1B1

c.850 A>C

p.N284H

novel

0.002

NA

4.1E-05

1

-

100

SLCO1B1

c.1159 G>A

p.A387T

novel

0.002

NA

1.7E-05

1

-

100

SLCO1B3

c.287 T>G

p.L96X

novel

0.002

NA

NA

1

-

100

(ª) Percentage of total tested DNA samples with NGS-determined genotypes concordant with TaqMan or Sanger derived genotypes.
Abbreviations: AF, allele frequency; dbSNP 137, Single Nucleotide Polymorphism database build 137; ExAC, Exome Aggregation
Consortium version 0.3; HET, heterozygous genotype; HOM, homozygous genotype; 1000G EUR, 1000 Genomes Project European dataset;
NA, not found in dbSNP 137, 1000G EUR, or ExAC database, respectively
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5.3.2

Analysis of variants in pharmacogenes

Genetic variation was assessed in 245 Caucasians (Figure 5-1, 5-3), and the SNVs
identified presented in Figure 5-3 according to functional effect, number of variants per
gene, or reported MAF in ExAC (if exonic). A total of 1089 unique SNVs were identified,
consisting of 605 non-synonymous (55.6%), 409 synonymous (37.6%), 13 splice-site
(1.2%), 13 stop gain or loss (1.2%), and 37 insertion-deletions (21 frameshift, 16 nonframeshift; 3.4%), as well as 12 known non-coding SNVs (1.0%) (Figure 5-3A). The
majority of variants (71%) were present only in heterozygous form. Among exonic variants
(Figure 5-3B), 25.9% of SNVs were common (ExAC MAF >5%), 14.2% occurred at a low
frequency (ExAC MAF ≥1 and 5), whereas 59.9% were either rare or novel (ExAC MAF
<1% or absent from ExAC or dbSNP137). MAFs in this study largely mirrored those
reported in much larger data sets (ExAC, 1000G) (Figure S5, Appendix E. According to
gene family or drug-related function, the CYP gene families had the most variants per
targeted base pairs, followed by the UDP glucuronosyltransferases (UGT) and ABC family,
then SLC family, while nuclear receptors were the least variable (Figure 5-3C).
Individually, among Phase I enzymes, CYP2D6 had the highest total number of SNVs (54)
and the highest number of rare or novel variants from our gene panel (Figure 5-3D), and
UGT1A4 had the most SNVs among Phase II enzymes. Within the SLC family, organic
cation transporter 1 (SLC22A1) showed the highest number of SNVs as well as rare or novel
SNVs among all SLC genes sequenced. Among transporter genes of the ABC family,
ABCC2 had the highest number of the SNVs with 34 variants.
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Figure 5-3. Analysis of variation in 245 subjects.
Analysis of genetic variation in 245 subjects assessed by PGxSeq. SNVs according to
functional effect (A), allele frequency reported in ExAC database (B), number of exonic
variants per target region (C), or gene (D).

‡

For UGT1A4, UGT1A6, UGT1A8, and

UGT1A9, only SNVs located within the first exon were counted while shared exons were
assessed only once with UGT1A1. ExAC, Exome Aggregation Consortium; MAF, minor
allele frequency; SNV, single nucleotide variant.
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5.3.3

In silico assessment of variants in pharmacogenes

Potential functional effects of the identified non-synonymous variants were assessed with
CADD, PolyPhen-2, and SIFT. Our results showed marked differences between the
prediction scores derived from these algorithms (Figure 5-4). However, the proportion of
rare (MAF < 1%) or novel variants that were categorized as possibly deleterious was greater
than the proportion of common (≥ 5%) or low frequency (≥ 1-5%) variants for all 3 tools
(CADD: p = 0.0004, PolyPhen-2: p = 0.0013, and SIFT: p = 0.0076, Figure S6, Appendix
E). The majority of pharmacogenes (87 out of 100) harbored at least one variant with a
CADD score > 20 (median, 2). Rare or novel variants that were predicted as deleterious
(CADD score > 20) were almost entirely observed in heterozygous form, with a median of
two SNVs per subject (min-max, 0 - 8) across the 100 genes (Figure S7, Appendix E).
Conversely, nearly all subjects (244 out of 245) had ≥ 1 common deleterious variant(s) in
the homozygous form, median three (0 - 11) SNVs per subject. Finally, we assessed
prediction scores among 12 CYP genes that account for the majority of known drug
oxidation reactions (Figure S7, Appendix E); on average, 15.8% (5 - 95th percentile, 9.1 20.4%) of SNVs with a CADD > 20 among individuals were located within these gene.
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Figure 5-4. In silico assessment of non-synonymous variants in pharmacogenes.
In silico assessment of non-synonymous variants in pharmacogenes identified by PGxSeq (N = 245). (A) Frequency distribution
of variants according to SIFT, PolyPhen-2, and CADD scores separated by minor allele frequency reported in the ExAC database.
Shaded regions represent the proportion of potentially functional variants (or deleterious), defined as a scaled CADD score > 20
(11), a SIFT score < 0.05 (12), or a PolyPhen-2 score > 0.85 (13)
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5.3.4

Variation in genes of clinical relevance

Among 9 clinically relevant genes for which Clinical Pharmacogenetics Implementation
Consortium (CPIC) prescribing guidelines for specific variant-drug combinations have
published, there are 29 “Level 1A/1B” variants categorized as having strong evidence for
influencing

drug

efficacy/response

and

prescribing

recommendations

(https://cpicpgx.org/alleles/, accessed Dec 25, 2016). We identified 19 out of these 29
actionable variants in our cohort, with 161 patients (65.7%) harboring at least one CPIC
level 1A/1B homozygous variant (Figure S8, Appendix E). We observed high read
coverage in regions comprising CPIC Level 1A/1B variants as well as rare or novel SNVs
with a CADD score >20 (Figure S10, Appendix E), illustrating the capacity of our gene
panel for comprehensive genetic profiling of pharmacogenes with clinical relevance.

5.3.5

SNV discovery in apixaban AF cohort

We applied our panel in a small group of AF patients with either a high (n = 6) or normal
(n = 6) apixaban plasma concentration phenotype (patient characteristics in Table 5-3).
Exonic and clinically relevant SNVs identified within the candidate genes selected for
exploratory analysis among the high and normal apixaban concentration groups is shown
Table 5-4. With the exception of a single variant within the NR1I2 gene (rs149041795)
belonging to an individual from the normal group, the remainder of nonsynonmous SNVs
that were found in ABCB1, ABCG2, CYP3A4, and CYP3A5 (no exonic variants were found
in NR1H4) were common and not predicted to be deleterious according to in silico
functional assessment tools. ABCG2 c.421C>A and CYP3A5*1 variants, have been
reported to be associated with higher and lower apixaban plasma concentrations in Japanese
127

AF patients, respectively (16, 17). We observed a slightly greater frequency of the ABCG2
c.421A allele in our high group compared to the normal group, and overall only one
individual in our normal group was a carrier of the CYP3A5*1 allele. We also identified
individuals that were carriers for common functionally established variants found within
our selected candidate genes. Two individuals within the high group were carriers of the
POR*28 variant. While within the normal group, one individual had a copy of the
CYP3A4*22 variant, and another individual had copy of the FXR/ NR1H4 c.-1 G>T variant.
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Table 5-3. Characteristics of apixaban-treated atrial fibrillation patients selected for
sequencing.
Characteristic

Apixaban concentration

Subjects, n
Age, median (IQR)
Sex, Male (%)
Weight, kg, median (IQR)

Normal

High

6

6

68 (65-77)

70 (64-77)

100.0%

33.3%

106.6 (74.9-133.6)

95.0 (79.6-114.4)

5 (100.0)

5 (83.3)

Apixaban Dose
5 mg twice daily, (%)
2.5 mg twice daily, (%)

0 (0)

Hours post dose, mean (min-max)

1 (16.6)

7.0 (6.3-7.8)

5.4 (3.2-8.9)

145.1 (120.2-155.8)

404.1 (260.8-445.3)

29.0 (24.0-31.2)

87.0 (70.3-93.0)

95.0 (70.0-105.0)

63.5 (51.8-82.0)

114.2 (78.16-183.2)

114.0 (95.8-132.3)

Apixaban plasma concentration
ng/ml, median (IQR)
ng/ml/mg, median (IQR)
Serum Creatinine, µmol/L, median (IQR)
Creatinine Clearance, mL/min, median (IQR)
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Table 5-4. Single nucleotide variants identified within high versus normal apixaban concentration groups.
Gene

ABCB1

c.2677 G>T

nonsynonymous

rs2032582

No. of
algorithms
predicting
as
damaginga
0/3

ABCB1

c.2677 G>A

nonsynonymous

rs2032582

0/3

NF

0.04

0.08

0.08

ABCB1

c.61 A>G

nonsynonymous

rs9282564

0/3

0.09

0.08

0.08

NF

ABCB1

c.3435 T>C

synonymous

rs1045642

(18, 19)†

0.47

0.5

0.50

0.58

ABCB1

c.2359 C>A

synonymous

rs200903110

-

NF

1.65E-05

0.08

NF

ABCB1

c.1236 T>C

synonymous

rs1128503

-

0.57

0.54

0.67

0.67

ABCB1

c.210 A>G

synonymous

rs2214102

-

0.9

0.94

0.92

0.83

ABCG2

c.421 C>A

nonsynonymous

rs2231142

(20, 21)†

0.1

0.12

0.25

0.17

CYP3A4

c.1242 C>G

synonymous

NF

-

NF

9.06E-05

0.08

NF

c.522-191 C>T

intronic

rs35599367

(22)†

0.05

NF

NF

0.08

c.423 A>G

rs6977165

-

0.03

0.05

NF

0.08

g.6986 A>G

loss of stop
codon
splice

rs776746

(23)†

0.95

NF

1.00

0.92

NR1H4

c.-1 G>T

5'UTR

rs56163822

(24)†

0.02

0.08

NF

0.08

NR1I2

c.1135 T>G

1/3

NF

2.00E-04

NF

0.08

CYP3A4

Allele Polymorphism

*22

CYP3A5
CYP3A5

*3

Type of SNV

dbSNP137

nonsynonymous rs149041795
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1000G
(Euro)
AF

ExAC

0.57

0.54

0.50

0.67

AF

High group
‡
AF

Normal
group ‡
AF

(n=6)

(n=6)

NR1I2

c.879 T>C

synonymous

rs4058490

-

1

1

1.00

1.00

c.1508 C>T

nonsynonymous

rs1057868

(25) †

0.3

0.36

0.25

NF

POR

c.15 A>G

synonymous

rs10262966

-

0.01

0.07

NF

0.08

POR

c.387 A>G

synonymous

rs1135612

-

0.26

0.27

0.50

0.17

POR

c.1455 T>C

synonymous

rs2228104

-

0.97

0.92

1.00

0.92

POR

c.1716 G>A

synonymous

rs1057870

-

0.33

0.38

0.17

0.67

POR

*28

‡ Colours range represents allele frequencies: (◻) not found or 0%, to 100% (◼)
Abbreviations: AF, allele frequency; dbSNP 137, Single Nucleotide Polymorphism database build 137; ExAC, Exome Aggregation
Consortium version 0.3; 1000G EUR, 1000 Genomes Project European dataset; NF, not found in dbSNP 137, 1000G EUR, ExAC database,
respectively, apixban group. (†) References for known functionally established SNVs in bracklets. (ª) Patient-specific SNV defined as
damaging if scaled CADD score >20 (11), a SIFT score <0.05 (12), or a PolyPhen-2 score >0.85 (13)
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5.4

Discussion

The principal findings of this study comprise: 1) the development of a
comprehensive targeted NGS gene panel for most clinically important
pharmacogenetic loci; 2) demonstrating the utility of this panel to simultaneously
detect common and rare variants with minimal to no artefacts resulting from difficult
to sequence regions; 3) demonstrating that PGxSeq performs at least as well as, and
usually better than, current standard pharmacogenetic assays; 4) our exploratory
analysis did not reveal likely deleterious SNV(s) within the selected candidate genes
in the apixaban-treated AF subjects that were sequenced, that may potentially
explain their observed elevated apixaban plasma concentration. Moreover, our
results support the high prevalence of rare or novel variants of potential functional
relevance within pharmacogenes.
Compared to traditional genotyping or sequencing strategies, the applied
targeted exome sequencing strategy enabled the comprehensive discovery of novel
rare SNVs as well as accurate genotyping for common, previously established
functional variation across exonic and intergenic regions in clinically important
pharmacogenes with fast and adequate performance. Available bioinformatics tools
further allowed customized utilization of sequencing data at a small or large scale,
i.e. the assessment of individual genotypes and genes of interest or a more exhaustive
pharmacogenetic analysis. Our target sequence included 29 clinically actionable
variants with recommendations to adjust dose or for alternative therapies. Nearly all
patients (97%) harboured one or more CPIC Level 1A/1B variant(s) confirming
recent findings from the eMerge-PGx study comprising extensive sequencing data
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from 5000 patients for 82 pharmacogenes (26). The multitude of other, newly
discovered candidate variants among CPIC genes in this study highlights the need
for comprehensive sequencing approaches to determine the likely more complex
genotype of a patient, while high-throughput experimental strategies are warranted
to screen and confirm effects of previously unreported genetic variation on protein
activity.
A significant number of pharmacogenetic variants detected in our total cohort
was either rare or novel (60%), and more than half (56%) resulted in amino acid
changes, supporting previous observations in larger datasets (1, 26-28). While the
proportion of SNVs with predicted effects on protein function differed among
applied in silico tools, differences in scoring have been previously observed and are
not surprising given the way these algorithms were derived (29). SIFT leverages the
evolutionary conservation of amino acids (12), PolyPhen-2 uses pathogenicity
information (13), while CADD is the most recent algorithm integrating conservation
metrics, regulatory information, and protein-level effect among others (11). A recent
study suggests that the in silico algorithms used here predict altered enzymatic or
transporter function with about 80% accuracy compared to in vitro assessment (29).
Among the possibly deleterious variants identified, rare or novel SNVs were more
likely to have functional effects than common or low frequency variants (Figure S6,
Appendix E), with 43.1 – 53.5 % of rare or novel SNV predicted to be deleterious
according to in silico algorithms. These findings are similar to a recent report
evaluating NGS data from thousands of individuals in 146 pharmacogenes, where
30% to 40% of rare variation was predicted to be functional (1). Moreover, we found
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that 94% of patients (231 of 246) carried at least one deleterious allele (CADD score
>20) in 12 CYP genes with key roles in drug metabolism (27, 30); these potentially
clinically relevant findings need to be followed up.
In this study, accurate variant and genotype calls were obtained in
pharmacogenes previously reported to be structurally problematic due to sequence
similarities but also due to highly variable or repetitive regions (29, 31-34). NGSderived genotypes were concordant with TaqMan results for all the common and/or
clinically relevant SNP that were tested. In addition, retrospective Sanger sequencing
confirmed 5 of the 5 rare variants identified by NGS in a subset of relevant genes.
Genetic profiling using any short-fragment sequencing platform is a widely
recognized challenge for NGS of pharmacogenes (31, 35), and requires sufficient
representation of mapped sequenced reads in the region of interest to ensure
accuracy. As expected, many members of the CYP, SULT and UGT gene families
were reported as harbouring 250-bp sequence fragments that map to more than one
place in the genome due to their sequence similarity, with regions that are up to 100%
identical (i.e. pseudogenes) predicted of being the most problematic (36). An
estimated 1.8% of our 422kb target sequence (69 exons in 19 genes) was found to
be susceptible to potential mismapping. Although our hybridization-based
enrichment strategy achieved a mean read coverage above 80x for most genes (98 of
100), the results also indicate that the mean value alone may not always correctly
indicate sufficiently even read coverage across the targeted coding region.
Specifically, for CES1 a mean DOC ≥ 80 × was observed, however 30.2% of its
targeted bases (Exon 12 - 14) showed a DOC <30 × indicating areas prone to higher
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error rates (Figure 5-2, Figure S3 Appendix E); a 95 - 100% sequence similarity
has been previously reported for CES1 exons 12 - 14 (36). Accordingly, high
homology regions may benefit from longer capture probes for hybridization-based
target enrichment to ensure appropriate capture and/or sequence read mapping.
Moreover, DOC for GSTM1 and GSTT1 were the lowest among all genes of our
panel. A previous report in a Korean population sample showed individuals with
GST gene deletion (GST*0) lacked coverage when assessed with NGS, while the
number of gene copies correlated the mean number of sequencing reads (29).
Deletions of GSTs are also prevalent among Europeans (MAF ~ 0.5 (37)), and we
noted 52% and 21% of our study group had near zero coverage for GSTM1 and
GSTT1, respectively, likely representing GST*0 carrier status (Figure S9, Appendix
E). While NGS is thought to be best suited for the detection of SNV, our findings
and most recent reports suggest that a read-depth based approach may be also used
for the identification of CNV as demonstrated for GSTs (29), the LDL receptor
(LDLR) (38) and various genes underlying retinal dystrophies (39) using gene
panels, as well as CYP2D6 utilizing whole-genome sequencing data (33). Our
findings highlight the need for monitoring targeted regions for low sequence
coverage, absent data or ambiguous calls to reduce false negative or positive findings
by defining test panel limitations in agreement with current clinical laboratory
standards for NGS (40).
Utilizing existing knowledge of apixaban’s metabolism and disposition, we took
a candidate gene approach to explore new, previously not recognized single
nucleotide variations that potentially correlate with apixaban concentration
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phenotype in a small subgroup of AF patients. While our sample size is too small to
draw any statistical inferences, we compared the variants identified between subjects
with high and normal concentration phenotypes using descriptive statistics. We did
not find rare or patient-specific deleterious SNV(s) within the seven candidate genes
in our subjects belonging to the high group that may potentially explain their
observed elevated apixaban plasma concentration. Furthermore, the distribution of
common clinically relevant SNVs identified between the high versus normal
concentration group were not always conceptually consistent with the known
functional effect of each variant. For instance, the POR*28 variant, which has been
reported to be associated with increased CYP3A activity (25), was observed only in
the high group (1 heterozygous, 1 homozygous). Theoretically, this variant would
be protective against higher apixaban plasma concentration. On the other hand, we
observed a higher frequency of the reduced function variant ABCG2 c.421 C>A
within the high concentration group compared to the normal group. This observation
is consistent with the high concentration phenotype, the ABCG2 gene codes for the
transporter, breast cancer resistance protein (BCRP), which plays a role in limiting
the absorption of apixaban in the gut (41). It is also worth noting that, even though
the in silico prediction tools that were used focus on the impact of nonsynonymous
SNVs, we cannot rule out the influence of synonymous or non-coding variants
(intronic, 5’ or 3’ untranslated regions). A classic example of this is the synonymous
ABCB1 c.3435C>T variant which has been implicated in altering the
pharmacokinetics and pharmacodynamics of a number of drugs (19, 42).
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While we show the potential application of targeted exome sequencing as a
comprehensive pharmacogenetic profiling tool, there are some limitations.
Validation of concordance was limited to variants in 41 loci in 21 genes in our
relatively small, mostly Caucasian sample, in contrast to previously reported multicenter studies that assessed hundreds of SNVs in larger populations (29, 32)
including commercially available DNA control samples (29, 40). At present, despite
high concordance rates for common CYP2D6 and CYP2C9 variants, we cannot
exclude false-positive variant calls. We intend to further evaluate our panel
considering intronic SNVs and CNVs for CYP2D6 in a larger, previously
characterized patient sample. Despite the small sample size, the herein observed
variation compared well to findings from larger data sets.
Next-generation sequencing platforms are starting to impact upon many clinical
fields, especially cancer and pediatrics. Bringing these technologies to clinical
pharmacogenetics represents a timely and logical convergence, especially given the
history of applied genetic concepts and molecular methods within the discipline.
Through comprehensive validation of performance and accuracy, results from our
study and others demonstrate the utility of targeted exome sequencing panels as
sensitive and reliable sequencing platforms for pharmacogenes (29, 32). But despite
the relative ease of the sequencing process, the time and effort required for postsequencing computational and bioinformatics data analyses are significant due to the
technical and interpretive complexity of NGS and the biology of some
pharmacogenetic gene targets. Moreover, as new variants are discovered using these
high-throughput detection methods, the need for standards in attributing
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pathogenicity together with development of tools for high-throughput functional
assessment and clinical validation are required before implementing findings to aid
therapeutic decision-making.
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Discussion and conclusion
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6.1 Summary and Discussion
6.1.1

Chapter Three

Factor Xa inhibitors (FXaIs), rivaroxaban and apixaban, represent a new class of oral
anticoagulants that are widely prescribed as an alternative to warfarin therapy for
stroke prevention in patients with atrial fibrillation (AF). An important advantage of
these drugs is that routine monitoring of anticoagulation response is not necessary.
Nevertheless, because of their mechanism of action, FXaI pharmacological effect
can be inferred based on the observed plasma drug concentration, yet there is a
paucity of data relating to variation in FXaI concentration among patients taking
these drugs in the post-market clinical setting. Therefore, the aim of Chapter Three
was to measure the extent of interpatient variation in the circulating FXaI plasma
concentrations of 243 atrial fibrillation patients prescribed rivaroxaban and apixaban
within a routine clinical care setting, and we hypothesized that this variation was
greater than that observed in clinical trials. In our routine-care setting rivaroxaban
and apixaban plasma concentrations tended to be more variable than those observed
in clinical trials, with approximately 12% of patients receiving rivaroxaban and 13%
of patients receiving apixaban exceeding the 95th percentile for the predicted
maximum plasma concentration observed in clinical trials. These results supported
our hypothesis, and accordingly we set out to identify additional clinical and
molecular determinants that more fully predict patients at risk for excessively high
or low FXaI concentration.
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6.1.2

Chapter Four

Renal function, age, sex, weight, as well as carrier status for functional genetic
polymorphisms within genes that code for proteins involved in the transport (ATP
binding cassette [ABC] G2 gene) and metabolism (cytochrome P450 [CYP] 3A5
gene) of apixaban have been demonstrated to impact the elimination of the drug in
humans as indicated by altered apixaban pharmacokinetics, and ultimately drug
exposure (1-4). Furthermore, as part of its metabolism, apixaban is primarily
oxidized by CYP3A enzymes (5, 6). However, the relationship between apixaban
blood concentrations and endogenous markers of CYP3A activity, as a predictor for
interindividual variability of apixaban exposure, has not been determined.
Accordingly, the aim of this chapter was to examine 4β-hydroxycholesterol (4βOHC) (as a marker for apixaban metabolism) along with the factors that are known
to impact apixaban exposure such as renal function, age, sex, weight, and common
genetic variation, in order to better explain the variation in concentration observed
within our apixaban-treated cohort. We hypothesized that 4β-OHC concentration
with clinical and genetic variables would better explain the variation in FXaI
concentration compared to clinical and genetic factors alone. We found a weak but
statistically significant correlation between plasma concentrations of apixaban and
4β-OHC, with higher 4β-OHC concentrations (higher CYP3A4 activity) associated
with lower apixaban concentrations. Moreover, multivariable linear regression
analysis demonstrated that 4β-OHC concentration was an independent predictor of
apixaban concentration in our cohort along with age, female sex, serum creatinine,
and amiodarone use. Weight, diltiazem use, as well as CYP3A4*22, CYP3A5*3,
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ABCB1 c.3435C>T, or ABCG2 c.421C>A carrier status were not significant
predictors of apixaban plasma concentration in our cohort. Although our findings
supported our hypothesis, we accounted for only 27.9% of the interindividual
variability in FXaI plasma concentration observed in our apixaban-treated AF cohort
(n = 119), leaving the majority of the variation unaccounted for.

6.1.3

Chapter Five

Clinical variables, common genetic variation, and 4β-hydroxycholesterol
concentration accounted for 31% of the interindividual variability in FXaI plasma
concentration observed in our apixaban-treated AF cohort (n = 119), leaving the
majority of the variation unaccounted for. Therefore, we hypothesized that part of
this unexplained variation was the result of certain individuals harbouring rare or
patient-specific functional single nucleotide variants (SNV) within candidate genes
encoding drug transporters and enzymes relevant to apixaban’s disposition. Recent
large-scale whole genome or exome sequencing studies have revealed that humans
harbor a large number of rare, and/or potentially deleterious variants in genes
relevant to drug disposition and response (7, 8). Targeted next-generation
sequencing (NGS) represents a new time- and cost-effective technology for detecting
common and rare genetic variation. In Chapter Five, we aimed to develop a targeted
sequencing approach to detect common and rare genetic variation in pharmacogenes
pertinent to drug disposition and response. We subsequently, applied this method for
single nucleotide variant discovery in a subgroup of apixaban-treated AF patients
with aberrantly high apixaban plasma concentrations compared to controls. Overall.
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we were able to generate a sufficient depth-of-coverage (DOC) >30x for 97.4% of
the target sequence, and for a select number of SNVs (32 common and 5 rare or
novel) we confirmed concordance between genotypes determined by NGS versus
TaqMan genotyping or Sanger sequencing. More specifically, our exploratory
analysis did not reveal likely deleterious SNV(s) within the selected candidate genes
in the apixaban-treated AF subjects that were sequenced, which may potentially
explain their observed elevated apixaban plasma concentration. Although this did
not support our hypothesis, at this point we cannot rule out the influence of
synonymous or non-coding variants (located in intronic, 5 or 3 prime untranslated
regions), as well as structural variants (copy number variations or large insertion and
deletions), as these variations could also have influence over gene expression, and
in turn the exposure of apixaban in these individuals. We were also limited by a small
sample size, sequencing a larger cohort would have allowed us to test for a difference
in the burden of SNVs within these candidate genes between our high and control
group.

6.2 Therapeutic implications
Since their approval, the use of direct-acting oral anticoagulants (DOACs), such as
apixaban and rivaroxban, for stroke prevention in patients with AF has rapidly
increased (9, 10), owing to their ease of prescribing and management. While warfarin
prescribing is complicated by routine INR testing and high interpatient variability in
the required therapeutic dosage (20-fold), DOACs offer fixed dosing (up to 2-fold)
without the need for routine monitoring. Although DOACs appeared to have a
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favourable risk-benefit profile in clinical trials compared to warfarin (11), major
bleeding is still a complication associated with DOAC use. Moreover, the patient
population that take DOACs in the post-market setting may vary greatly with their
co-morbidities and extensive co-medications from those within clinical trials. As
prescribing trends in clinical practice continue to favour the use of DOACs, the
number of bleeding events associated with them is likely to increase as well.
Identifying factors that increase the DOAC-associated bleeding risk in patients
before prescribing these drugs can help to mitigate adverse drug events. Aside from
non-DOAC related factors that increase bleeding risk such as advanced age,
pharmacodynamic interactions from co-medications, and medical conditions or
procedures with a pre-existing risk for hemorrhage; prolonged elevation of DOAC
plasma concentrations will exacerbate the risk of bleeding associated with the use of
these medications (12-15).
As observed in Chapter Three, when dosing according to clinical guidelines, the
measured FXaI plasma concentrations for a subgroup of AF patients taking apixaban
and rivaroxaban within a routine care setting will likely fall in the extremes of FXaI
drug exposure. Although, our study was not designed to identify an association
between FXaI concentration and bleeding or stroke events, this relationship has been
described in the product monograph of apixaban (12), rivaroxaban (15), and more
recently published for edoxaban (a novel FXaI inhibitor) (16). However, without an
established threshold for efficacy (thrombosis) or safety (bleeding), such as the one
established for warfarin with INR, making dose adjustments or constructing dose
algorithms based on observed FXaI concentrations will remain to be clinically
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challenging. Ultimately, our findings provide support for a need to establish a
therapeutic range of FXaI plasma concentrations for which the risk of bleeding and
stroke are at the lowest. On the other hand, physicians can currently use FXaI plasma
concentration as a means to ensure patient compliance, especially among those
patients experiencing stroke or transient ischemic attacks while prescribed
rivaroxaban and apixaban.
In Chapter Four, we attempted to characterize the inter-individual variability in
the FXaI plasma concentrations observed in our apixaban-treated AF cohort from
Chapter Three. We found that the majority of the explainable variation in apixaban
concentration was accounted for by age and renal function which are currently
assessed as part of apixaban dose selection. In addition to this, our results
demonstrated that measuring endogenous biomarkers of CYP3A4 activity such as
4β-hydroxycholesterol may help determine whether an unexpectedly low apixaban
plasma concentration is the result of high CYP3A4 activity. This can provide
physicians with an additional layer of evidence to support increasing apixaban
dosage or a change in medication to one that is independent of CYP3A4 metabolism.
Concomitant use of amiodarone was associated with higher apixaban plasma
concentration in our AF cohort. Patients who experience bleeding while taking
amiodarone with apixaban, may benefit from therapeutic drug monitoring as a
method for dose adjustment, especially if they have elevated apixaban
concentrations.
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6.3 Future direction
Future prospective studies involving AF patients within routine care that focus on
rivaroxaban and apixaban exposure in relation to clinically relevant outcomes (major
bleeding, stroke, death) are needed to determine the FXaI concentration thresholds
for safety (bleeding) and efficacy (stroke). Not only will this help elucidate the true
clinical significance of the observed variation in FXaI plasma concentration that was
found in our studies, but it will also accelerate the field of research involved in
characterizing FXaI interpatient variation.
The study we carried out in Chapter three was observational, involving
patients who were recruited during their routine care visits. As such, we were limited
in our ability to account for the effect of adherence as well as inaccurate selfreporting of time of last-dose on the drug concentration. Therefore, it remains
possible that unreported missed doses or drug intake without food (rivaroxaban only)
may explain some of the inter-patient variability especially in patients with very low
plasma concentrations. Prospective studies, that ensure both patient adherence to
dosing and sampling of blood to obtain either trough FXaI plasma concentrations or
an area-underneath-the-curve, would likely reduce the proportion of unexplained
variation.
Recent work carried out in a Japanese AF population have reported the
ABCG2 421A/A and CYP3A5*1/*1 genotype to be associated with higher and lower
trough apixaban concentrations, respectively (4, 17). While we did not observe an
association between these functional polymorphisms and variability in apixaban
plasma concentration, this may in part be due to the fact that there weren’t many
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variant carriers in our cohort. Further studies in larger AF cohorts including more
variant carriers from different ancestries will help confirm the effect of these
polymorphisms on apixaban plasma concentration, while in vitro and animal studies
characterizing the molecular mechanism behind the altered plasma concentration
(i.e., decreased absorption and/or reduced excretion) would strengthen Ueshima et
al., observations in human. For instance, in vitro experiments examining the
difference in the vectorial transport of apixaban within human intestinal and kidney
cell models expressing wildtype ABCG2 (breast cancer resistance protein, BCRP)
or the c.421C>A variant.
Through developing our targeted NGS panel (Chapter Five) we discovered the
majority of individuals that were sequenced had some degree of burden in terms of
deleterious SNVs across their pharmacogenes. These variants ranged from clinically
actionable SNVs, with a strong evidence for influencing drug efficacy/response, to
newly discovered candidate SNVs that were predicted to be deleterious according to
in silico functional assessment tools. The multitude of variants detected in each
individual highlights the need for comprehensive sequencing approaches to
determine the likely more complex genotype of a patient. But despite the relative
ease of the sequencing process, the time and effort required for post-sequencing
computational and bioinformatics data analyses are significant; complicated by the
technical and interpretive complexity of NGS and the biology of some
pharmacogenes. One of the areas that will benefit from developing more integrated
software for post-sequencing data extraction is the identification of copy number
variations from NGS data, including partial gene insertions and deletions –
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eventually becoming a growing area of research as it pertains to genotyping (18-20).
Additionally, the field of pharmacogenetics will likely benefit from in silico
prediction tools that tailor the impact of an amino acid change in terms of its
influence on drug-protein substrate specificity for a drug of question – perhaps by
incorporating knowledge of the regio-specific interactions between drug substrates
and the relevant proteins involved in their disposition pathway. This will assist in
filtering worthwhile candidate variants for investigation in those FXaI-treated AF
subjects who demonstrate unexpectedly high or low drug plasma concentrations.
Ultimately, as variants are discovered using these high-throughput detection
methods, the need for standards in attributing pathogenicity together with
development of tools for high-throughput functional assessment and clinical
validation are required before implementing findings to aid therapeutic decisionmaking.

6.4 Conclusion
Today, FXaIs are prescribed at fixed doses without the need to assess the degree of
anticoagulation. As prescribing trends in clinical practice continue to favour the use
of FXaIs for preventing cardioembolic stroke in patients with atrial fibrillation, the
number of adverse events associated with these drugs is likely to increase as well.
The identification of factors that drive variation in FXaI exposure and response will
provide the basis for a safe, yet efficacious approach to dose selection. The studies
presented within this thesis provide insight into the factors that drive variation in

152

FXaI concentration, and may serve as a framework for future investigations
regarding personalizing FXaI anticoagulation therapy.
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Appendix C
Multiple linear regression coefficients for apixaban plasma concentration in atrial
fibrillation patients (n = 119).

Predictor variable

B

95% CI

P-value

Dose

0.109

0.073, 0.146

<0.001

Hours post dose

-0.016

-0.035, 0.002

0.086

Age, years

0.008

0.004, 0.012

<0.001

Sex, Female

0.069

-0.006, 0.144

0.069

Weight, kg

<0.001

-0.002, 0.002

0.985

Serum creatinine, µmol/L

0.002

0.001, 0.003

<0.001

ABCB1 c.3435C>T , per allele

0.001

-0.049, 0.051

0.972

ABCG2 c.421C>A, 1 or 2 allele

0.063

-0.018, 0.144

0.125

CYP3A4*22, 1 or 2 allele

0.027

-0.069, 0.124

0.574

CYP3A5*3, 1 or 2 allele

0.002

-0.111, 0.116

0.971

Amiodarone use

0.128

0.027, 0.230

0.014

Diltiazem use

0.015

-0.080, 0.110

0.756

Adjusted R squared 0.235.
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Appendix D
Detailed methods
Sample collection
Genomic DNA (gDNA) was obtained from venous blood samples of 245
Caucasian subjects following written informed consent. We initially evaluated
sequencing performance and accuracy of variant detection in the first 48 subjects −
this was our validation cohort. Following this, all 245 subjects that were sequenced
were used to evaluate genetic variation in terms of population allele frequencies and
predicted functional effect. Then we carried out candidate gene SNV discovery in a
subgroup of 12 AF patients with a known apixaban drug concentration phenotype.
This study was approved by the Research Ethics Board of Western University,
London, Canada.

Gene selection, capture probe design and enrichment method
We used the Nextera Rapid Capture Custom Enrichment Kit (Illumina, San
Diego, CA) for the enrichment of genomic regions of 100 genes encoding major
cytochrome P450 (CYP) enzymes, phase II conjugation enzymes, drug transporters
of the solute carrier (SLC) and ATP binding cassette (ABC) families as well as
regulatory proteins of relevance to variability in drug ADME (absorption,
distribution,

metabolism,

excretion)

and

response.

In

addition,

regions

encompassing 14 known functional promoter or intronic SNVs were included (Table
1).
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Table S1. Promoter and intronic SNVs included in probe design.
Gene

Promoter
regions

Intronic
regions

Allele dbSNP137

Positionᵃ

CYP1A2 *1C
CYP2C19 *17
UGT1A1 *28

rs2069514
rs12248560
rs8175347

UGT1A1
VDR
VDR
VKORC1
NR1H4

*60

rs4124874
rs11568820
rs4516035
rs9923231
rs56163822

Chr15:75038220
Chr10:96521657
Chr2:234668881:
234668882
Chr2:233757013
Chr12:47908762
Chr12:47906043
Chr16:31096368
Chr12:100493323

CYP1A2
CYP3A4
VKORC1
CYP3A5
CYP2D6
NR1I2

*1F
*22

rs762551
rs35599367
rs9934438
rs776746
rs28371725
rs2276707

Chr15:74749576
Chr7:99768693
Chr16:31093557
Chr7:99672916
Chr22:42127803
Chr3:119815306

*3
*41

(ᵃ) Chromosome position based on the GRCh37 assembly
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A total of 10,207 capture probes (80 bp) were custom-designed using the
Illumina Design Studio (Illumina, San Diego, CA) comprising 722 kilobases (kb) of
sequence per sample (Genomic coordinates can be found in Table S1, Supplemental
Digital Content 1). Exons of all coding isoforms were targeted for selected genes
including 300-bp intronic (flanking each exon) and 250 bp of 5' and 3' untranslated
regions (UTR). Chromosomal coordinates were obtained from University of
California Santa Cruz (UCSC) genome browser using the GRCh37/hg19 human
genome assembly. DNA library preparation and subsequent target-capture
sequencing was conducted at the London Regional Genomics Center, London,
Ontario, as previously described (1). Briefly, DNA samples were processed in runs
in batches of 12 or 24 samples. After serial dilutions, DNA was adjusted to a final
concentration of 5.0 ± 1 ng/µl using the Qubit DNA kit (Invitrogen, Eugene, OR).
DNA was enzymatically fragmented, polymerase chain reaction (PCR)-amplified
with individual sample barcodes, equimolar pooled, hybridized to the biotinylated
capture probes, pooled using streptavidin beads, and PCR-amplified again to select
the final target sequence. Resulting libraries were quantified, and loaded on to a
standard flow-cell on the Illumina MiSeq Sequencer (Illumina, San Diego, CA)
using 2 x 300 bp or 2 x 150 bp paired-end chemistry.

Base calling, sequence alignment and variant detection
Prior to the alignment of reads to the reference genome, sequencing performance
metrics were assessed. For each run, cluster density (1000/mm2), total number of
reads passing instrument filters and per base quality score (also Phred score, Q;
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describes the probability of a sequencing error as a measure of base call accuracy)
was obtained. Paired-end sequenced reads were separated according to samplespecific barcodes and sequencing data downloaded as FASTQ files that were further
assessed with the quality control tool, FastQC (2), including base quality across
reads, per sequence GC content, sequence length distribution and duplication level
(3).
Alignment of sequencing reads and variant calling were performed using the
CLC Bio Genomics Workbench 7.0 (CLC Bio, Aarhus, Denmark) through a customautomated workflow. FASTQ files were imported and mapped to the reference
human genome (GRCh37/hg19 build). Using default algorithms (i.e. Local
Realignment and Remove Duplicate Mapped Reads), initial read mapping was
further optimized around insertion-deletion mutations (indels) and PCR duplicates
removed. To further ensure accuracy of variant and genotype calling, quality-based
variant detection tools were employed with the following parameters: diploid
organism, probability of non-reference allele ≥ 95% (versus sequencing error), ≥ 10fold coverage (10 x), ≥ 30% read frequency, and ≥ 30 per base quality score at the
variant location. Resulting sequence variation reports were exported in variant call
format (VCF) for downstream annotation.
Coverage (also read depth) or depth-of-coverage (DOC) was defined as the
number of reads mapped to a genomic position following alignment of sequenced
reads and removal of duplicate reads. Reads that were non-specific matches (mapped
to more than one location of hg19 reference genome) or missing the paired read were
excluded from this calculation. For every subject, a Coverage Summary Report
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along with a base-by-base Coverage Table were exported. Coverage analysis was
restricted to coding regions, including 10 bp before and after each exon, and 250 bp
of 3' and 5'UTR. We assessed inter-subject and intra-subject variability of DOC
across target sequence by sequencing cluster (n = 12 or 24), and the mean (SD) for
each gene. As an additional indicator of low coverage regions within a gene we
expressed DOC as the percentage of targeted bases having mean DOC < 30 ×.

Variant annotation and in silico functional assessment
Functional annotation of SNVs was carried out using ANNOVAR (4) through in
silico prediction algorithms such as Combined Annotation Dependent Depletion
(CADD) (5), Sorting Intolerant from Tolerant (SIFT) (6), and PolyPhen-2 (7), and
variant frequency among different populations were determined utilizing large
genomic databases (RefSeq, dbSNP137, 1000 Genomes, Exome Aggregation
Consortium [ExAC]; obtained July 8, 2015). SNVs with a CADD Phred score
(scaled) greater than 20 (5), a SIFT score of less than 0.05 (6), or a PolyPhen-2 score
of greater than 0.85 (7) were considered as potentially functional variants (altering
protein function), and herein defined as " deleterious". Variants were classified as 1)
non-synonymous (coding variants resulting in amino acid change), 2) synonymous
(coding variants without amino acid changes), 3) frameshift deletion or insertion (indel), 4) splicing (3 nucleotides within an intron-exon boundary), 5) stop gain or loss,
or 6) functional intronic or promoter variants. Coding variants were further grouped
by MAF reported in the ExAC database as common (MAF ≥ 5%), low frequency
(1% ≤ MAF > 5%), or the combined category of rare (MAF < 1%) and novel (absent
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from ExAC and dbSNP build 137 databases). In silico functional assessment was
restricted to protein-coding genetic variation and gain or loss of a stop codon.
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Concordance assessment
To assess concordance of NGS results, orthogonal genotyping was performed using
TaqMan allelic discrimination for 32 common functionally validated or clinically
relevant SNVs. Rare NGS variants were confirmed retrospectively by Sanger
sequencing within 7 pharmacogenes. Polymerase chain reaction conditions and
primers for Sanger sequencing and TaqMan assay IDs are listed in Table 2, and
Table 3 respectively.
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Table S2. Polymerase chain reaction conditions and primers used for Sanger sequencing of rare NGS variants.
Abbreviations: dbSNP137, Single Nucleotide Polymorphism database build 137; PCR, polymerase chain reaction; FOR,
forward primer; REV, reverse primer.
Gene
dbSNP137/Positionᵃ PCR Target
Exon

RefSeq

Primer set

Product

(5' to 3')

Size

Ref.

(bp)
ABCB1
CYP2D6ᵇ

rs55852620

rs5030867

SLCO1B1 Chr12:21350002

SLCO1B1 Chr12:21355448

SLCO1B3 Chr12:21011433

(24/26) NM_000927

(6/9)

(8/15)

NM_000106

NM_006446

(10/15) NM_006446

(3/14)

FOR

GAGAATTAATCTATGTGATTATGG-

REV

GTATTTAACATCTCATACAGTCAGAG

FOR

GCTAACTGAGCACA-

REV

CCGGCCCTGACACTCCTTCT

FOR

AATCTTACATGACTTACGTTCAC-

REV

CCACTTGGAATACAGTATTTAG

FOR

TCTGCTTTCACTTTACTTCTTCC-

REV

GAATAAGGAGAGGAAAGTAAAAAC

NM_001009562 FOR

GGGCATTCAGTTCTACTAGA-

REV

TAATAAATGGCTCAGAGCTG

263

(8)

577

(9)

242

(10)

195

(10)

233

(11)

(ᵃ) Chromosome position based on the GRCh37 assembly
(ᵇ) CYP2D6 PCR method included a pre-amplification of the whole gene using long template PCR using the forward
(GGTAAGGGCCTGGAGCAGGAA) and reverse primer (GCCTCAACGTACCCCTGTCTC) described by Stüven et
al, (12), followed by purification and subsequent sanger sequencing using the primers listed above.
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Table S3. TaqMan assay ID for the common functionally validated clinically
relevant SNVs.
Gene

dbSNP

TaqMan Assay ID

ABCB1
ABCC2
ABCG2
ABCG2

rs1045642
rs2273697
rs2231142
rs2231137

CYP2B6
CYP2B6
CYP2C19
CYP2C19
CYP2C9
CYP2C9
CYP2D6
CYP2D6
CYP2D6
CYP2D6
CYP2D6
CYP3A4
CYP3A5
CYP4F2
DPYD
FXR
LXRα
POR
PXR
SLCO1B1
SLCO1B1
SLCO1B3
SLCO2B1
TPMT
TPMT
VDR
VDR
VKORC1

rs3211371
rs3745274
rs12248560
rs4244285
rs1799853
rs1057910
rs35742686
rs3892097
rs5030656
rs1065852
rs28371725
rs35599367
rs776746
rs2108622
rs67376798
rs56163822
rs2279238
rs1057868
rs2276707
rs2306283
rs4149056
rs7311358
rs12422149
rs1800460
rs1142345
rs11568820
rs4516035
rs9923231

C___7586657_20
C__22272980_20
C__15854163_70
Custom design
(13)
C__30634242_40
C___7817765_60
C____469857_10
C__25986767_70
C__25625805_10
C__27104892_10
C__32407232_50
C__27102431_D0
C__32407229_60
C__11484460_40
C__34816116_20
C__59013445_10
C__26201809_30
C__16179493_40
C__27530948_10
C__25598386_10
C__15967384_10
C___8890131_30
C__15882324_10
C___1901697_20
C__30633906_10
C__25765587_40
C___3101331_10
C__30634116_20
C_____19567_20
C___2880808_10
C___2880805_10
C__30403261_20
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Statistical analysis
Analyses were performed using the software R (14) and GraphPad Prism 6
(La Jolla, USA). Differences in the proportion of possibly deleterious variants
between common, low frequency, and rare or novel variant groups was assessed
using a Chi-squared test (statistical significance, P value <0.05). Pearson correlation
coefficient was used to determine association between our study allele frequencies
with those reported in the ExAC database (statistical significance, two-tailed P value
<0.05).
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Appendix E
Figure S1. Mean Phred quality score for sequencing reads per read length. Yellow arrow indicates Phred base quality score ≥30 (99.9%
sequencing accuracy) up until the 150bp read position. Base quality declines for sequencing reads that were more than 150bp in length,
resulting in a mean ≥30 Phred quality score of 62.6% (Run 1), 65.1% (Run 2), and 63.2% (Run 3).
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Figure S2. Frequency distribution of the percentage of guanine and cytosine nucleotides per sequenced read in 48 subjects. Arrows
indicate the five samples with aberrantly higher GC content.
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Figure S3. Mean (±SD) depth of coverage (DOC) across the targeted sequence for CES1, CBR1, CYP1A2 and showing
the inaccessible target regions.
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Figure S4. Data represented a mean subject DOC (±SD) across target sequence. Inter-subject and intra-subject variability
of DOC across the target sequence in the validation cohort (n = 48). Matching coloured arrows indicate the five samples
with aberrantly higher GC content. (‡) 1 sample repeated (PGST395).
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Figure S5. Similarity of observed minor allele frequencies (MAF) in relation to the
reported MAF in 1000 Genomes Project (1000G) and Exome Aggregation
Consortium (ExAC) datasets.
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Figure S6. Rare or novel variations had greater proportion of deleterious in silico prediction scores (n = 245).
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Figure S7. Zygosity of the potentially deleterious variants (CADD scaled score greater than 20) per subject (n = 245), showing there
were more heterozygous variants per subject compared to homozygous. Single nucleotide variants (SNV) found in Cytochrome P450
(CYP) enzymes (CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2J2, CYP3A4, CYP3A5, and
CYP4F2 ) were highlighted in yellow.
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Figure S8. Number of Clinical Pharmacogenetics Implementation Consortium (CPIC) “Level 1A/1B” variants (categorized as having
strong supporting evidence for affecting drug efficacy/response as well as specific prescribing recommendations
https://cpicpgx.org/alleles/) found in 245 subjects separated by zygosity.
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Figure S9. Histogram of the GSTM1 and GSTT1 gene coverage as a fraction total subject coverage in 45 subjects (excluding 3
subjects with aberrant GC content; PGST362, PGST357, PGON131).
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Figure S10. Mean (±SD) depth-of-coverage (DOC) across the targeted sequence of select
genes (n = 24; from Sequencing Run 1 and Run 2). Vertical lines represent (red) CPIC
level 1A/1B clinically actionable variant, and (green) NGS identified variants with scaled
CADD score greater than 20, along with their minor allele frequencies (MAF) if found in
our cohort (70 subjects). Possibly deleterious variants in CYP2D6 (●).
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